Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs

BACKGROUND

Alzheimer's disease is a clear and present danger to older adults, and has a profound socio-economic impact. Existing therapies are limited in efficacy. Early identification of subjects at risk may open the door to preventive approaches. Short-term memory dysfunction is a key early feature of Alzheimer's disease. Psychiatric patients may be at higher risk for memory dysfunction and subsequent Alzheimer's disease due to the negative effects of stress and depression on the brain.

Existing drugs have potential utility in other diseases and disorders. Biomarkers can serve as companion diagnostics for clinical trials for the development of new medications and also for repurposing existing drugs for other diseases and disorders.

Accordingly, methods are needed for early identification of memory dysfunction and Alzheimer's disease. Additionally, methods are needed for identifying and repurposing existing drugs and natural compounds for use as treatments of other disorders and diseases.

SUMMARY

The present disclosure is generally directed at methods for assessing memory dysfunction and early identification/prediction of risk for future memory dysfunction, Alzheimer's disease and cognitive decline, using computer assisted methods that derive scores based on biomarker data, in some instances blood biomarker data. Further, the present disclosure relates to methods for matching individuals with drugs to reduce the risk of and mitigate memory dysfunction, Alzheimer's disease and cognitive decline, and methods for monitoring response to treatment. Finally, the invention relates to new methods of use for candidate drugs and natural compounds repurposed for treating memory dysfunction, Alzheimer's disease and cognitive decline. All the above-mentioned methods may include computer-assisted methods that generate scores based on analyses of the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approach by gender, and by diagnosis, are disclosed.

In one aspect, the present disclosure is directed to a method for identifying a biomarker for Alzheimer's disease, the method comprising: obtaining a first biological sample from a subject and administering a first memory test to the subject; obtaining a second biological sample from the subject and administering a second memory test to the subject; identifying a first cohort of subjects by identifying subjects having about 20% change in a memory retention characteristic as determined by a difference between the first memory test and the second memory test; identifying candidate biomarkers in the first cohort by identifying biomarkers having a change in expression.

In one aspect, the present disclosure is directed to a method to reduce the risk of and mitigate memory dysfunction, Alzheimer's disease, and cognitive decline in a subject in need thereof, the method comprising administering a therapy to the subject, the therapy being selected from the group consisting of one or more compounds from Tables 5A1-A5, and 5B1-B5, and 5C1-C2.

In one aspect, the present disclosure is directed to a computer-implemented method for assessing a low memory state in a subject, and for assessing risk of future Alzheimer Disease and cognitive decline in a subject, the method comprising: computing a score based on RNA level, protein level, DNA methylation, a single nucleotide polymorphism, a panel of at least one biomarker in one of Table 2, Table 4A and Table 4B, and combinations thereof in a sample obtained from a subject; computing a score based on a reference expression level of the panel of biomarkers; and identifying a difference between the score in the sample obtained from the subject and the score in the reference sample, wherein the difference in the score in the sample obtained from the subject and the score in the reference sample indicates a risk for a low memory state in the subject. In other aspects, the present disclosure is directed to a method for assessing and mitigating memory dysfunction, Alzheimer's disease, and cognitive decline in a subject in need thereof, comprising determining an expression level of a panel of biomarkers listed in Table 2, Table 4, or Table 5 in a sample, wherein the expression level of the biomarkers in the sample is different relative to a reference expression level, identifying the subject currently having or at risk of having in the future memory dysfunction, Alzheimer's disease, and cognitive decline based on a biomarker panel score relative to a biomarker panel score of a reference; and administering to the subject a therapy being selected based on the score from the group consisting of one or more compounds from Tables 5A1-A5, and 5B1-B5, and 5C1-C2.

In some aspects, of the disclosed methods, the therapy is lithium, an antidepressant, pioglitazone, sulfadimidine, SB-203580, mesalazine, metamizole, levonorgestrel, meglumine, lymecycline, rimexolone, ketanserin, quipazine, cisapride, proparacaine, tenoxicam, bexarotene, an omega-3 fatty acid, salsolidine, ginkgolide A, icariin, docosahexaenoic acid, or combinations thereof.

In some aspects, the sample comprises a peripheral tissue, blood, saliva, cerebrospinal fluid (CSF), serum, urine, or stool.

In other aspects, the present disclosure is directed to a composition comprising one or more compounds from Tables 5A1-A5, and 5B1-B5, and 5C1-C2 for use in a method for treating memory dysfunction, Alzheimer's disease, and cognitive decline.

In some aspects, the compound comprises lithium, an antidepressant, pioglitazone, sulfadimidine, SB-203580, mesalazine, metamizole, levonorgestrel, meglumine, lymecycline, rimexolone, ketanserin, quipazine, cisapride, proparacaine, tenoxicam, bexarotene, an omega-3 fatty acid, salsolidine, ginkgolide A, icariin, docosahexaenoic acid, or combinations thereof. In some aspects, the compound comprises one or more of the compounds from Tables 5A1-A5, and 5B1-B5, and 5C1-C2.

DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1C are illustrations depicting the methods described in the present disclosure. FIG. 1A depicts the cohorts used in study, depicting flow of discovery, prioritization, and testing of biomarkers. FIG. 1B depicts the differential gene expression in the discovery cohort-number of genes identified with differential expression (DE) and absent-present (AP) methods with an internal score of 2 and above. In FIG. 1C, the pyramid on the left depicts the number of discovery step probesets, identified based on their score for tracking memory, with a maximum of internal points of 6 (33% (2 pt), 50% (4 pt) and 80% (6 pt)), and the pyramid on the right depicts prioritization with CFG for prior evidence of involvement in AD.

FIG. 2 is a schematic illustrating the interaction networks for top candidate biomarkers (n=111 top genes, 136 probe sets).

FIGS. 3A and 3B are graphs depicting the best single biomarkers for predictors of state (low memory retention state) (FIG. 3A) and trait (future neuropsychosis) (FIG. 3B). Bold—top CFG scoring biomarkers on the list (CFG≥12, n=21 probe sets). Bar graph shows best predictive biomarkers in each group. *Nominally significant p<0.05. Table underneath the figures displays the actual number of biomarkers for each group whose ROC AUC p-values (FIG. 3A) and Cox Regression Odds Ratio p-values (FIG. 3B) are at least nominally significant. Some female diagnostic groups were not shown in the graph as they did not have subjects to be tested or any significant biomarkers. Cross-sectional was based on levels at one visit. Longitudinal was based on levels at multiple visits (integrates levels at most recent visit, maximum levels, slope into most recent visit, and maximum slope). Dividing lines represent the cutoffs for a test performing at chance levels (white), and at the same level as the best biomarkers for all subjects in cross-sectional (gray) and longitudinal (black) based predictions. All biomarkers performed better than chance. Biomarkers performed better when personalized by gender and diagnosis.

FIGS. 4A and 4B are graphs depicting RHEB as a possible personalized biomarker predictor for risk of future AD in Males with Schizophrenia. Subject Phchp098 was a male with schizophrenia (SZ) tested in 2009. He was first diagnosed with paranoid schizophrenia in 1977. In 2016, he was also diagnosed by neuropsychological testing with ADRD and impaired decision-making capacity. At that time, he was 66 years old. Subject was the only one so far with an ADRD diagnosis in the independent replication follow-up cohort. RHEB levels were Z-scored by gender and diagnosis. Subject Phchp098 had the highest levels of RHEB in testing from all the subjects with future neuropsychological testing (FIG. 4A), and in fact the highest level of RHEB from all the 111 subjects in that cohort (FIG. 4B).

FIG. 5 is a schematic illustrating the pharmacogenomics of the top biomarkers modulated by existing drugs.

FIG. 6 is a schematic diagram depicting the matching of patients to drugs, the pharmacogenomics.

DETAILED DESCRIPTION

Disclosed are methods for identifying biomarkers for memory dysfunction and early identification of Alzheimer's disease. Also disclosed are methods using biomarker expression levels for identifying and treating one or more populations or subpopulations for reducing risk of and mitigating memory dysfunction, Alzheimer's disease, and cognitive decline. Further, the present disclosure relates to methods for identifying candidate drugs and natural compounds repurposed for treating memory dysfunction, Alzheimer's disease and cognitive decline. The methods are useful for early detection of Alzheimer's disease in subjects and identifying existing drugs and natural compounds that can be repurposed for treating subjects for memory dysfunction, Alzheimer's disease and cognitive decline.

In one aspect, the present disclosure is directed to a method for identifying a one or more biomarker(s) for Alzheimer's disease, the method comprising: obtaining a first biological sample from a subject and administering a first memory test to the subject; obtaining a second biological sample from the subject and administering a second memory test to the subject; identifying a first cohort of subjects by identifying subjects having about 20% change in a memory retention characteristic as determined by a difference between the first memory test and the second memory test; identifying candidate biomarker(s) in the first cohort by identifying biomarkers having a change in expression.

The method can further include prioritizing the candidate biomarkers by identifying candidate biomarkers known to be associated with Alzheimer's disease.

A suitable memory test is Hopkins Verbal Learning Test-Revised (HVLT-R). Suitable subjects include those having a psychiatric disorder. Suitable subjects can be male subjects and female subjects.

As used herein, “sample” or “biological sample” refers to the sample from which biomarkers are measured. In some embodiments, the sample is blood. In some embodiments, the sample can be saliva, cerebrospinal fluid (CSF), serum, urine, stool, and/or another bodily fluid. In some embodiments, the sample is a peripheral tissue.

As used herein, “expression level of a biomarker” refers to the process by which a gene product is synthesized from a gene encoding the biomarker as known by those skilled in the art. The gene product can be, for example, RNA (ribonucleic acid) and protein. Expression level can be quantitatively measured by methods known by those skilled in the art such as, for example, northern blotting, amplification, polymerase chain reaction, microarray analysis, tag-based technologies (e.g., serial analysis of gene expression and next generation sequencing such as whole transcriptome shotgun sequencing or RNA-Seq), Western blotting, enzyme linked immunosorbent assay (ELISA), and combinations thereof. In some embodiments, the biomarker is a polymorphic biomarker profile. In some embodiments, the polymorphic biomarker profile includes one or more single nucleotide polymorphisms (SNPs), one or more restriction fragment length polymorphisms (RFLPs), one or more short tandem repeats (STRs), one or more variable number of tandem repeats (VNTRs), one or more hypervariable regions, one or more minisatellites, one or more dinucleotide repeats, one or more trinucleotide repeats, one or more tetranucleotide repeats, one or more simple sequence repeats, or one or more insertion elements. In some embodiments, the methods further include establishing a profile of biomarkers.

As used herein, “a reference expression level of a biomarker” refers to the expression level of a biomarker established for a subject with no known memory dysfunction, Alzheimer's disease and cognitive decline, expression level of a biomarker in a normal/healthy subject with no known memory dysfunction, Alzheimer's disease and cognitive decline as determined by one skilled in the art using established methods as described herein, and/or a known expression level of a biomarker obtained from literature. The reference expression level of the biomarker can further refer to the expression level of the biomarker established for a high risk subject for memory dysfunction, Alzheimer's disease and cognitive decline, including a population of high risk subjects. The reference expression level of the biomarker can also refer to the expression level of the biomarker established for a low risk memory dysfunction, Alzheimer's disease and cognitive decline subject, including a population of low risk subjects. The reference expression level of the biomarker can also refer to the expression level of the biomarker established for any combination of subjects such as a subject with no known memory dysfunction, Alzheimer's disease and cognitive decline, expression level of the biomarker in a normal/healthy subject with no known memory dysfunction, Alzheimer's disease and cognitive decline, expression level of the biomarker for a subject who has no memory dysfunction, Alzheimer's disease and cognitive decline at the time the sample is obtained from the subject, but who later exhibits memory dysfunction, Alzheimer's disease and cognitive decline. For example, depending on the biomarker(s) selected, the difference in the expression level of the biomarker(s) can indicate an increased (greater) risk that a subject will develop symptoms consistent with memory dysfunction, Alzheimer's disease and cognitive decline. Conversely, depending on the biomarker(s) selected, the difference in the expression level of the biomarker(s) can indicate a decreased (lower) risk that a subject will develop symptoms with or memory dysfunction, Alzheimer's disease and cognitive decline.

In some embodiments, the methods can further include genotyping the subject. The genotyping can be performed by methods such as sequencing, nucleic acid array and PCR. The nucleic acid can be double-stranded DNA, single-stranded DNA, single-stranded DNA hairpins, DNA/RNA hybrids, RNA, RNA hairpins and cDNA. The presence or absence of the one or more nucleic acids can be determined by sequencing, nucleic acid array and PCR. Suitable nucleic acid arrays include DNA arrays such as, for example polymorphism arrays. Suitable polymorphism arrays include SNP arrays, for example.

In one aspect, the present disclosure is directed to a method for identifying a subject suspected of having Alzheimer's disease, the method comprising: obtaining a first biological sample from a subject; obtaining a second biological sample from the subject; and identifying the subject by identifying a change in expression of at least one of RAB7A, NPC2, TGFB1, GAP43, ARSB, PERI, GUSB, MAPT, FCGR1A, UBE2L3, NKTR, RHEB, PTGS2, RGS10, ITPKB, KIDINS220, GSK3B, SERTAD3, APOE, UBE2I, FOXO3, THRA, IGF1, NPTX2, GSTM3, BACE1, PSEN1, GFAP, TREM2, NOCT, CEP350, PPP2R2B, NRP2, CTSS, VEGFA, and combinations thereof.

The method can further include administering a memory test to the subject when the first biological sample is obtained from the subject and administering the memory test to the subject when the second biological sample is obtained from the subject; and determining a change in a memory retention characteristic as determined by a difference between the first memory test and the second memory test. Suitably, the memory test is Hopkins Verbal Learning Test-Revised (HVLT-R). The HVLT-R can be used to determine a ‘Low Memory Retention’, which as used herein, can also be called ‘Low Memory State’ or ‘Low Memory Retention state’ or ‘Memory Retention measure.’ Suitably, the subject can have about 20% change in a memory retention characteristic as determined by a difference between the first memory test and the second memory test.

Suitable subjects include those having a psychiatric disorder. Suitable subjects can be male subjects and female subjects.

Suitable subjects include subjects over 21 years old.

In one aspect, the present disclosure is directed to a method of prophylactically treating a subject for Alzheimer's Disease, the method comprising: obtaining a first biological sample from a subject; obtaining a second biological sample from the subject; and identifying a change in expression of at least one of RAB7A, NPC2, TGFB1, GAP43, ARSB, PERI, GUSB, MAPT, FCGR1A, UBE2L3, NKTR, RHEB, PTGS2, RGS10, ITPKB, KIDINS220, GSK3B, SERTAD3, APOE, UBE2I, FOXO3, THRA, IGF1, NPTX2, GSTM3, BACE1, PSEN1, GFAP, TREM2, NOCT, CEP350, PPP2R2B, NRP2, CTSS, VEGFA, and combinations thereof; identifying a difference between the expression level of the at least one of RAB7A, NPC2, TGFB1, GAP43, ARSB, PERI, GUSB, MAPT, FCGR1A, UBE2L3, NKTR, RHEB, PTGS2, RGS10, ITPKB, KIDINS220, GSK3B, SERTAD3, APOE, UBE2I, FOXO3, THRA, IGF1, NPTX2, GSTM3, BACE1, PSEN1, GFAP, TREM2, NOCT, CEP350, PPP2R2B, NRP2, CTSS, VEGFA, and combinations thereof, and a reference expression level of at least one of RAB7A, NPC2, TGFB1, GAP43, ARSB, PERI, GUSB, MAPT, FCGR1A, UBE2L3, NKTR, RHEB, PTGS2, RGS10, ITPKB, KIDINS220, GSK3B, SERTAD3, APOE, UBE2I, FOXO3, THRA, IGF1, NPTX2, GSTM3, BACE1, PSEN1, GFAP, TREM2, NOCT, CEP350, PPP2R2B, NRP2, CTSS, VEGFA, and combinations thereof; and administering a therapy to the subject.

Suitable therapies can include a drug, a natural compound, and combinations thereof. Suitable drugs can include lithium, an antidepressant, pioglitazone, levonorgestrel, and bexarotene, for example. Suitable natural compounds can include omega-3 fatty acid (e.g., docosahexaenoic acid), salsolidine, ginkgolide A, and icariin, for example.

In one aspect, the present disclosure is directed to a method for identifying a biomarker (e.g., a blood biomarker) for short-term memory dysfunction, the method comprising: obtaining a first biological sample from a subject and administering a first memory test to the subject; obtaining a second biological sample from the subject and administering a second memory test to the subject; identifying a first cohort of subjects by identifying subjects having about 20% change in a memory retention characteristic as determined by a difference between the first memory test and the second memory test; identifying candidate biomarkers in the first cohort by identifying biomarkers having a change in expression; and prioritizing the candidate biomarkers by identifying candidate biomarkers known to be associated with short-term memory.

The can further include prioritizing the candidate biomarkers by identifying candidate biomarkers known to be associated with short-term memory.

A suitable memory test is Hopkins Verbal Learning Test-Revised (HVLT-R).

Suitable subjects include those having a psychiatric disorder. Suitable subjects can be male subjects and female subjects.

In one aspect, the present disclosure is directed to a method for identifying a drug candidate for repurposing for use in treating Alzheimer's disease, the method comprising: obtaining a first biological sample from a subject and administering a first memory test to the subject; obtaining a second biological sample from the subject and administering a second memory test to the subject; identifying a first cohort of subjects by identifying subjects having about 20% change in a memory retention characteristic as determined by a difference between the first memory test and the second memory test; identifying a candidate biomarker in the first cohort by identifying a biomarker having a change in expression; identifying a drug having an effect on the biomarker; and identifying the drug as a candidate for treating Alzheimer's disease.

Suitable drugs include those that reduce the activity of the biomarker. Other suitable drugs include those that increases the activity of the biomarker.

The biomarker is at least one of RAB7A, NPC2, TGFB1, GAP43, ARSB, PERI, GUSB, MAPT, FCGR1A, UBE2L3, NKTR, RHEB, PTGS2, RGS10, ITPKB, KIDINS220, GSK3B, SERTAD3, APOE, UBE2I, FOXO3, THRA, IGF1, NPTX2, GSTM3, BACE1, PSEN1, GFAP, TREM2, NOCT, CEP350, PPP2R2B, NRP2, CTSS, VEGFA, and combinations thereof.

In one aspect, the present disclosure is directed to a method for identifying a subject having or at risk for having cognitive decline, the method comprising: obtaining a first biological sample from a subject and administering a first memory test to the subject; obtaining a second biological sample from the subject and administering a second memory test to the subject; identifying a first cohort of subjects by identifying subjects having about 20% change in a memory retention characteristic as determined by a difference between the first memory test and the second memory test; identifying candidate biomarkers in the first cohort by identifying biomarkers having a change in expression; and prioritizing the candidate biomarkers by identifying candidate biomarkers known to be associated with cognitive decline.

The method can further include prioritizing the candidate biomarkers by identifying candidate biomarkers known to be associated with cognitive decline.

A suitable memory test is Hopkins Verbal Learning Test-Revised (HVLT-R).

In one embodiment, the subject also has a psychiatric disorder.

Suitable subjects are male subjects and female subjects.

The cognitive decline can be cognitive impairment dysfunction, mild cognitive impairment, and dementia.

In one aspect, the present disclosure is directed to a method of prophylactically treating a subject for cognitive decline, the method comprising: obtaining a first biological sample from a subject; obtaining a second biological sample from the subject; and identifying a change in expression of at least one of RAB7A, NPC2, TGFB1, GAP43, ARSB, PERI, GUSB, MAPT, FCGR1A, UBE2L3, NKTR, RHEB, PTGS2, RGS10, ITPKB, KIDINS220, GSK3B, SERTAD3, APOE, UBE2I, FOXO3, THRA, IGF1, NPTX2, GSTM3, BACE1, PSEN1, GFAP, TREM2, NOCT, CEP350, PPP2R2B, NRP2, CTSS, VEGFA, and combinations thereof; and administering a therapy to the subject.

Suitable therapies include drugs, natural compounds, and combinations thereof. In one embodiment, the subject can also have a psychiatric disorder. In s

Suitable subjects are male subjects and female subjects.

The cognitive decline is cognitive impairment dysfunction, mild cognitive impairment, and dementia.

The method can further include obtaining a memory impairment score from the subject by administering a memory impairment screening test to the subject. A suitable memory test is Hopkins Verbal Learning Test-Revised (HVLT-R).

In some embodiments, the method includes converting the Z-scored expression value of each biomarker into a numeric score of 1, 0.5 or 0, depending if the biomarker's expression is in the high-risk range, intermediate risk range, or low risk range, based on the reference expression values for the particular biomarker. In some instances, this score is multiplied by the biomarker's CFE (Convergent Functional Evidence) score, which serves as a weight, as not all biomarkers are equally important. See such CFE scores in Table 2. In some instances, the resulting value is then divided by the maximum possible CFE score for that particular biomarker, yielding a weighted score. In some instances, the weighted scores are added for all the biomarkers in the panel, and divided by the number of markers in the panel. In some instances, the panel score is multiplied by 100 to generate a value between 0 and 100, which can be compared to a reference score.

In some embodiments, for each biomarker in the panel, a list of existing psychiatric medications that modulate the expression of the biomarker in the direction of high memory can be identified bioinformatically. In some instances, each such medication can be given a score commensurate with the biomarker score, i.e. 1 or 0.5 or 0. In some instances, such a medication can modulate more than one biomarker. In some intances, an average score for each medication can be calculated based on its effects on the biomarkers in the panel, and multiplied that by 100, resulting in a score of 0 to 100 for each medication. In some embodiments, psychiatric medications can be matched to the expression of biomarkers in a particular patient and ranked in order of impact on the panel.

In some embodiments, large drug gene expression databases such as Connectivity Map and NIH LINCS can be interrogated, as related to particular biomarkers that are positive as high risk in the panel in a particular patient. In some instances, this can lead to an individualized drug repurposing, identifying and ranking for fit using a score. As such, a new method of use for non-psychiatric medications and nutraceuticals can be identified and used in a particular patient to reduce risk and mitigate memory dysfunction, Alzheimer's Disease and cognitive decline.

EXAMPLES
Materials and Methods

Two independent cohorts of psychiatric disorders patients, one for Discovery of candidate biomarkers, and one for Testing of top biomarkers (for predicting memory state, and predicting future positive neuropsychological testing for cognitive impairment) were used (FIG. 1, Table 1).

TABLE 1

Aggregate demographics. Cohorts used in study.

Number

Age in years at

of

time of lab visit

subjects

Mean

(number

(SD)
T-test for age at

Cohorts
of visits)
Gender
Diagnosis
Ethnicity
(Range)
time of lab visit

Discovery

Discovery Cohort
159
Male =
131 (414)
BP =
52 (187)
EA =
107 (347)
50.26

(Within-Subject
(with
Female =
28 (82)
MDD =
23 (64)
AA =
47 (135)
(8.97)

Changes in
496

SZA =
35 (97)
Asian =
1 (2)
(22-66)

Memory
visits)

SZ =
27 (82)
Hispanic =
3 (9)

Retention)

PTSD =
14 (43)
Biracial =
1 (3)

MOOD =
5 (14)

PSYCH =
3 (9)

Testing

Independent
127
Male =
97 (176)
BP =
37 (73)
EA =
86 (162)
50.48
Low Memory

Testing Cohort
(238
Female =
30 (62)
MDD =
24 (48)
AA =
40 (73)
(8.2)
Retention (n = 68) vs.

For Predicting
visits)

SZA =
27 (48)
Asian =
1 (3)
(23-74)
Others (n = 170)

State (Low

SZ =
23 (42)

Low Memory
0.703983

Memory

PTSD =
12 (20)

Retention =
50.9 (10.9)

Retention ≤40

MOOD =
2 (5)

Others =
50.32 (6.83)

at Time of

PSYCH =
2 (2

Assessment)

Independent
56
Male =
47 (91)
BP =
11 (23)
EA =
33 (64)
55.6
Future Positive

Testing Cohort For
(111
Female =
9 (20)
MDD =
13 (26)
AA =
23 (47)
(5.0)
Neuropsych

Predicting Trait
visits)

SZA =
11 (20)

(40-74)
Testing (n = 11) vs.

(Future Positive

SZ =
15 (30)

Neuropsych Testing
Others (n = 100)

Neuropsych

PTSD =
5 (10)

Positive =
54.2 (6.05)
0.411644

Testing for

MOOD =
1 (2)

Others =
55.8 (4.89)

Dementia in

All Years

Following

Assessment)

BP-Bipolar; MDD-Major depressive disorder; SZA-schizoaffective disorder; SZ-schizophrenia, PTSD-post-traumatic stress disorder.

The psychiatric subjects were part of a larger longitudinal cohort of adults. Subjects were recruited from the patient population at the Indianapolis VA Medical Center. All subjects understood and signed informed consent forms detailing the research goals, procedure, caveats and safeguards, per IRB approved protocol. Subjects completed diagnostic assessments by an extensive structured clinical interview —Diagnostic Interview for Genetic Studies, and up to six testing visits, 3-6 months apart or whenever a new psychiatric hospitalization occurred. At each testing visit, they received a series of rating scales, including a Hopkins Verbal Learning Test (HVLT-R, see FIG. 6), and blood was drawn. Whole blood (10 ml) was collected in two RNA-stabilizing PAXgene tubes, labeled with an anonymized ID number, and stored at −80° C. in a locked freezer until the time of future processing. Whole-blood RNA was extracted for microarray gene expression studies from the PAXgene tubes, as detailed below.

For this study, the within-subject longitudinal discovery cohort, from which the biomarker data were derived, consisted of 159 subjects (131 males, 28 females) with multiple testing visits (a total of 496), who each had at least one 20% change in the Retention measure of HVLT from one consecutive testing visit to another.

The independent test cohort for predicting state (Low Memory Retention) consisted of 127 subjects (97 males, 30 females), demographically matched with the discovery cohort, with one or more testing visits (for a total of 238 visits). Low Memory Retention was defined as a score of ≤40 (FIG. 1, Table 1).

The independent test cohort for predicting trait (future positive neuropsychological testing for cognitive impairment) consisted of 56 subjects (47 males, 9 females), demographically matched with the discovery cohort, with one or more testing visits in our lab (for a total of 111 visits). Positive neuropsychological testing was defines as a diagnosis of MCI, ADRD (Alzheimer Disorder Related Dementia), or other dementia upon neuropsychological testing done in a clinical setting, triggered by clinical concerns as part of regular clinical care (FIG. 1, Table 1).

Medications. The subjects in the discovery cohort were all diagnosed with various psychiatric disorders (see, Table 1), and had various medical co-morbidities. Their medications were listed in their electronic medical records, and documented at the time of each testing visit. Medications can have a strong influence on gene expression. However, the discovery of differentially expressed genes was based on within-subject analyses, which factor out not only genetic background effects but also minimizes medication effects, as the subjects rarely had major medication changes between visits. Moreover, there was no consistent pattern of any particular type of medication, as the subjects were on a wide variety of different medications, including both psychiatric and non-psychiatric. Furthermore, the independent validation and testing cohorts' gene expression data was Z-scored by gender and diagnosis before being combined, to normalize for any such effects.

RNA extraction. Whole blood (2.5-5 ml) was collected into each PaxGene tube by routine venipuncture. PaxGene tubes contain proprietary reagents for the stabilization of RNA. RNA was extracted and processed as previously described (Niculescu et al., Mol. Psychiatry 2015 20(11): 1266-1285; Levey et al., Mol. Psychiatry 2016 21(6): 768-785; Le-Niculescu et al., Mol. Psychiatry 2013 18(12): 1249-1264).

Microarray. Microarray work was carried out as previously described (Niculescu et al., Mol. Psychiatry 2015 20(11): 1266-1285; Levey et al., 2016; Le-Niculescu et al., 2013.

For biomarker discovery, the subject's score from the HVLT-DR Retention measure was assessed at the time of blood collection (FIG. 1). Using a 20% change threshold in Retention, differences in gene expression between visits were analyzed, using a powerful within-subject design, then an across-subjects summation (FIG. 1).

Data was analyzed in two ways: an Absent-Present (AP) approach, and a differential expression (DE) approach. The AP approach may capture turning on and off of genes, and the DE approach may capture gradual changes in expression. A powerful within-subject design, then an across-subjects summation score was used for probe sets. Affymetrix microarray data was imported as CEL. files into Partek Genomic Suites 6.6 software package (Partek Incorporated, St Louis, Mich., USA). Using only the perfect match values, a robust multi-array analysis (RMA) by gender and diagnosis, background corrected with quantile normalization and a median polish probe set summarization of all chips, was performed to obtain the normalized expression levels of all probe sets for each chip. Then, to establish a list of differentially expressed probe sets a within-subject analysis was conducted using a fold change in expression of at least 1.2 between high stress and low stress visits within each subject. Probe sets that had a 1.2-fold change were then assigned either a 1 (increased in high stress) or a −1 (decreased in high stress) in each comparison. These values were then summed for each probe set across all the comparisons and subjects, yielding a range of raw scores. The probe sets above the 33.3% of scores received an internal score of 2 points, those above 50% received 4 points, and those above 80% received 6 points. R scripts were developed to automate and conduct all these large dataset analyses in bulk, and checked against human manual scoring.

Gene Symbol for the probe sets were identified using NetAffyx (Affymetrix) for Affymetrix HG-U133 Plus 2.0 GeneChips, followed by GeneCards to confirm the primary gene symbol. In addition, for those probe sets that were not assigned a gene symbol by NetAffyx, GeneAnnot or UCSC were used to obtain gene symbols, followed by GeneCard. Genes were then scored using the manually curated CFG databases as described below (FIG. 1).

For prioritization using Convergent Functional Genomics (CFG) was used for prioritization. Databases of the human gene expression/protein expression studies (postmortem brain, peripheral tissue/fluids: CSF, blood and cell cultures), human genetic studies (association, copy number variations and linkage), and animal model gene expression and genetic studies, published to date on psychiatric disorders was manually curated. Only findings deemed significant in the primary publication, by the study authors, using their particular experimental design and thresholds, were included in the databases. The databases include only primary literature data and do not include review papers or other secondary data integration analyses to avoid redundancy and circularity. These large and constantly updated databases have been used in a CFG cross validation and prioritization platform (FIG. 1). For this study, data from 213 papers on AD were present in the databases at the time of the CFG analyses (August 2018) (human genetic studies—62, human brain tissue studies—49, human peripheral tissue/fluids—83, non-human genetic studies—4, non-human brain tissue studies—13, non-human peripheral tissue/fluids—2). Analyses were performed as previously described (Niculescu et al., Mol. Psychiatry 2015; 20(11): 1266-1285; Levey et al., Mol. Psychiatry 2016 21(6): 768-785).

Biomarkers to be carried forward were selected after the prioritization step, using as threshold a CFG score ≥10 (n=138 probe sets, 112genes). Of these, the top candidate biomarkers had a CFG score ≥12 (n=23 probe sets, 18 genes). In Step 3, testing, Low Memory Retention state, and future positive neuropsychological testing for cognitive impairment were then predict in independent cohorts.

In Step 3, testing, the test cohort for predicting Low Memory Retention (state), and the test cohort for predicting Future Positive Neuropsychological Testing (trait), were assembled out of data that was RMA normalized by gender and diagnosis. The cohort was completely independent from the discovery and validation cohorts, there was no subject overlap with them. Phenomic (clinical) and gene expression markers used for predictions were Z scored by gender and diagnosis, to be able to combine different markers into panels and to avoid potential artefacts due to different ranges of expression in different gender and diagnoses. Markers were combined by simple summation of the increased risk markers minus the decreased risk markers. Predictions were performed using R-studio. For cross-sectional analyses, marker expression levels, z-scored by gender and diagnosis were used. For longitudinal analyses, four measures were combined: marker expression levels, slope (defined as ratio of levels at current testing visit vs. previous visit, divided by time between visits), maximum levels (at any of the current or past visits), and maximum slope (between any adjacent current or past visits). For decreased markers, the minimum rather than the maximum were used for level calculations. All four measures were Z-scored, then combined in an additive fashion into a single measure. The longitudinal analysis was carried out in a sub-cohort of the testing cohort consisting of subjects that had at least two test visits.

Predicting State Low Memory. Receiver-operating characteristic (ROC) analyses between marker levels and memory state were performed by assigning subjects visits with a HVLT Retention score of ≤40 into the Low Memory category (using the pROC package of R; Xavier Robin et al. BMC Bioinformatics 2011) (see, FIG. 3). Additionally, a one-tailed t-test was performed between Low Memory group vs. the rest, and Pearson R (one-tail) was calculated between Memory scores and markerlevels.

Predicting Trait Future Positive Neuropsychological Testing for Cognitive Impairment. Analyses was conducted for predicting future positive neuropsychological testing performed as part of routine clinical care in subjects that had follow-up in the VA system using electronic medical records follow-up data of the study subjects (up to 12.81 years from initial visit). Analyses between genomic and phenomic markers measures (cross-sectional, longitudinal) at a specific testing visit and future positive neuropsychological test were performed as described below, based on assigning if subjects had a future positive neuropsychological test for cognitive impairment or not. A Cox regression was performed using the time in days from the lab testing visit date to the positive neuropsychological testing date. The hazard ratio was calculated such that a value greater than 1 always indicated increased risk for positive neuropsychological testing, regardless if the biomarker was increased or decreased in expression. A hazard ratio (also called odds ratio, O.R.) can be calculated using biomarker expression information as a means for predicting risk of future development of Alzheimer's and related disorders. Additionally, a Pearson R (one-tail) correlation was performed between positive neuropsychological testing frequency (number of positive neuropsychological tests divided by duration of follow-up) and marker levels.

Pharmacogenomics. Which of the top biomarkers from Table 3 (n=38 probe sets) known to be modulated by existing drugs were analyzed using the CFG databases, and using Ingenuity Drugs analyses (Tables 2 and 3).

TABLE 2

Top Biomarkers. Convergent Functional Evidence for Relevance to Short-Term Memory Tracking and Alzheimer Disease (AD).

Step 1

Step 3

Discovery
Step 2
Best significant
Step 3

in blood
External
prediction of
Best significant
Other
Pharmacogenomics

(Direction
CFG
state
predictions of
psychiatric
Drugs that

of change
evidence
Low memory
trait future
and related
modulate

tracking
for
retention
positive
disorders
the

increased
involve-
ROC AUC/
neuropsych
evidence
biomarker

memory)
ment in
p-value
OR/OR p-value
(change in
(Change in

method/
AD
up to 6 pts
Up to 6 pts
opposite
Same

score/
score
ALL
ALL
direction to
Direction to
CFE

Genesymbol/

%
up to
4 pts gender
4 pts gender
increased
Increased
polyevidence

Gene name
Probeset
up to 6 pts
12 pt
2 pts gender/Dx
2 pts gender/Dx
memory)
Memory)
score

RAB7A
227602_at
(I)
7

ALL

Gender

BP
TCA
21

RAB7A,

AP/2

L: (17/111)
Male
Brain
Valproate

member RAS

43.8%

0.66/1.73E−02

C: (7/91)
arousal

oncogene

(I)

Gender Dx

2.51/3.08E−02
depression

family

DE/4

F-BP

MDD

69.6%

L: (2/9)

neuropathic

1/2.02E−02

pain

M-BP

L:
(1/27)

1/4.76E−02

M-PSYCHOSIS

L: (8/27)

0.76/1.68E−02

M-SZ

L: (5/14)

0.8/3.59E−02

M-SZA

C: (12/33)

0.67/4.98E−02

NPC2
200701_at
(D)
8

ALL

Aging

20

Niemann-

DE/6

L: (17/111)

alcohol

Pick disease,

80.8%

0.65/2.38E−02

SZ

type C2

Gender

Male

L: (12/79)

0.65/4.65E−02

Gender Dx

M-MDD

L: (3/18)

0.96/7.58E−03

M-SZA

L: (3/13)

0.9/2.13E−02

TGF131
203084_at
(I)
9

ALL

Aging
Omega-3
19

transforming

AP/4

C: (68/238)

ASD
fatty acids

growth

54.5%

0.58/2.88E−02

BP

factor beta 1

Gender

Chronic

Male

stress

C: (53/176)

Depression

0.6/2.29E−02

Longevity

Gender Dx

Pain

M-PTSD

Phencyclidine

C:

(4/10)

Suicide

1/5.26E−03

PTSD

M-SZ

SZ

C: (15/34)

0.68/3.99E−02

GAP43
204471_at
(I)
7

Gender Dx

ALL

BP
Valproate
19

growth

DE/4

M-SZA

C:

(11/111)

depression
Benzodiazepines

associated

50.8%

L: (3/13)

2.07/2.08E−02

SZ

protein 43

0.867/3.15E−02

L: (3/50)
stress

6.14/1.51 − 02

Gender

Male

C: (7/91)

2.94/1.17E−02

L: (3/43)

5.54/1.47 − 02

Gender-Dx

M-Psychosis

L: (2/22)

5.4/2.96 − 02

M-SZ

L: (2/13)

4.08/3.83 − 02

ARSB
1554030_at
(I)
6

ALL

Alcohol

18

arylsulfatase

DE/6

L: (17/111)

Depression

B

91.7%

0.72/2.19E−03

MDD

Gender

Suicide

Male

L: (12/79)

0.74/4.92E−03

Gender Dx

F-BP

L: (2/9)

0.93/3.95E−02

M-PSYCHOSIS

L:

(8/27)

0.88/1.04E−03

M-SZ

L:

(5/14)

0.8/3.59E−02

M-SZA

L: (3/13)

1/5.61E−03

PER1
242832_at
(I)
6

Gender

Gender

Alcohol
Lithium
18

period

DE/4

Female

Male
Anxiety
Clozapine

circadian

61.3%

C:
(15/62)

L: (3/43)
ASD
Quetiapine

clock 1

0.7/9.17E−03
5.2/4.97E−03
Autism
Avibactam

Gender Dx

BP

F-BP

Circadian

C: (6/19)

abnormalities

0.83/1.13E−02

Depression

M-BP

MDD

L: (1/27)

PTSD

1/4.76E−02

Sleep

Duration

Suicide

SZ

GUSB
202605_at
(D)
8

ALL

Aging
Clozapine
18

glucuronidase,

DE/4

L: (17/111)

Methamphetamine

beta

55.7%

0.65/2.16E−02

Gender

Female

L: (5/32)

0.79/2.29E−02

Gender Dx

F-BP

C: (6/19)

0.81/1.76E−02

M-MDD

L: (3/18)

0.89/1.91E−02

MAPT
203930_s_at
(I)
10

ALL

Aging
Lithium
18

microtubule

DE/2

L:
(11/111)
Alcohol
Omega-3

associated

33.7%

1.96/2.95E−02
Intellect
fatty acids

protein tau

Gender

MDD

Male

Methamphetamine

C:

(7/91)
Phencyclidine

3.54/4.62E−02
Stress

Gender Dx

Suicide

M-PSYCHOSIS
SZ

C: (5/47)

2.84/3.34E−02

M-SZ

C:

(4/27)

4.65/4.06E−02

FCGR1A
216951_at
(I)
7

ALL

17

Fc fragment

DE/4

L:

(3/49)

of IgG, high

64.6%

20/3.50−02

affinity Ia,

Gender

receptor

Male

(CD64)

L:

(3/40)

15.4/4.37E−02

UBE2L3
200682_s_at
(D)
4

ALL

Aging
Clozapine
16

ubiquitin

DE/6

L: (17/111)

Alcohol

conjugating

91%

0.63/4.13E−02

ASD

enzyme

Gender

Depression

E2L3

Male

Stress

L: (12/79)

SZ

0.65/4.92E−02

Gender Dx

M-BP

C:

(10/54)

0.7/2.25E−02

M-SZA

L: (3/13)

0.9/2.13E−02

NKTR
1570342_at
(D)
4

ALL

Alcohol

16

natural killer

AP/6

C:

(68/238)

BP

cell

85%

0.59/1.40E−02

Depression

triggering

Gender

MDD

receptor

Male

Social

C:

(53/176)

Isolation

0.62/5.55E−03

Stress

Gender Dx

Suicide

M-BP

SZ

C: (10/54)

0.68/3.56E−02

M-PSYCHOSIS

C:

(27/67)

0.63/3.19E−02

M-PSYCHOSIS

L: (8/27)

0.72/3.55E−02

M-SZ

C:

(15/34)

0.72/1.38E−02

M-SZ

L:

(5/14)

1/1.35E−03

RHEB
243008_at
(D)
4

ALL

Suicide
Antidepressants
16

Ras homolog

AP/6

C: (11/111)
Pain

enriched in

84.4%

1.51/3.05E−02
SZ

brain

(D)

Gender

DE/4

Male

64.1%

C: (7/91)

1.63/2.46E−02

Gender Dx

M -PSYCHOSIS

C: (5/47)

2.12/5.45E−03

L: (2/22)

9.69/1.68E−02

M-SZ

C: (4/27)

1.82/1.78E−02

L:

(2/13)

6.22/3.32E−02

PTGS2

1554997_a_at
(D)
10

Gender Dx

Aggression
Antipsychotics
16

prostaglandin-

DE/4

M-PTSD

Alcohol
Lithium

endoperoxide

76%

C: (4/10)

ASD
Vorinostat

synthase 2

0.88/2.75E−02

BP

(prostaglandin

Chronic

G/H

Fatigue

synthase and

Syndrome

cyclooxygenase)

Depression

Depression-

Related

MDD

Neurological

Pain

Phencyclidine

Social

Isolation

Stress

Stress

Substances/

Addictions

Suicide

RGS10
214000_s_at
(I)
6

ALL

Aging

16

regulator of

DE/4

L: (17/111)

BP

G-protein

63.5%

0.7/3.89E−03

Female

signaling 10

Gender

specific

Male

interpersonal-

L:

(12/79)

traumas

0.74/4.73E−03

Methamphetamine

Gender Dx

Post-

F-BP

Deployment

L: (2/9)

PTSD

0.93/3.95E−02

PTSD

M-BP

Stress

L: (1/27)

Suicide

1/4.76E−02

SZ

M-MDD

L: (3/18)

0.87/2.53E−02

M-SZ

C: (15/34)

0.68/3.70E−02

MAPT

203928_x_at
(I)
10

Gender Dx

Aging
Lithium
16

microtubule

DE/4

F-BP

Alcohol
Omega-3

associated

57.5%

C: (6/19)

Intellect
fatty acids

protein tau

0.81/1.76E−02

MDD

Methamphetamine

Phencyclidine

Stress

Suicide

SZ

ITPKB
232526_at
(I)
6

ALL

Aging

16

inositol-

DE/4

L:

(17/111)

Alcohol

trisphosphate

51.9%

0.73/1.60E−03

MDD

3-kinase B

Gender

Phencyclidine

Male

Stress

L: (12/79)

Suicide, SZ

0.7/1.44E−02

SZ

Female

L: (5/32)

0.79/2.29E−02

Gender Dx

M-BP

L: (1/27)

1/4.76E−02

KIDINS220
214932_at
(I)
6

Gender Dx

Gender

Alcohol
Clozapine
16

kinase D-

DE/4

F-BP
Male
MDD

interacting

51.9%

L: (2/9)

C: (7/91)
Psychosis

substrate

0.93/3.95E−02
2.49/3.78E−02
Pain

220 kDa

Gender-Dx

Suicide

M-BP

Stress

C:

(2/16)

6.06/4.18 − 02

GSK3B

209945_s_at
(D)
10

Gender Dx

Aging
Astaxanthin-
16

glycogen

DE/4

M-SZA

Alcohol
DHA

synthase

50.3%

L: (3/13)

ASD
Antipsychotics

kinase 3 beta

0.93/1.40E−02

BP
Lithium

BP, SZ
Omega-3

MDD
fatty acids

Stress
Ketamine

Suicide
lipoteichoic

SZ
acid

Valproate

enzastaurin,

glycogen

synthase

kinase-3beta

inhibitor

SERTAD3
219382_at
(D)
5

Gender

Alcohol

15

SERTA

DE/6

Female

ASD

domain

81.4%

L: (5/32)

Aging

containing 3

0.79/2.29E−02

Gender Dx

F-BP

C: (6/19)

0.81/1.76E−02

F-PSYCHOSIS

L:

(2/13)

1/1.50E−02

F-SZA

L:

(2/8)

1/2.28E−02

APOE

212884_x_at
(D)
11

Gender Dx

Aggression
Omega-3
15

apolipoprotein

AP/2

M-PTSD

Aging
fatty acids

E

34.1%

C: (4/10)

Alcohol

0.88/2.75E−02

Anxiet

Gender Dx

ASD

M-SZ

BP

L: (5/14)

Brain

0.89/9.82E−03

arousal

MDD

PTSD

Stress

Suicide

SZ

TBI

UBE2I

233360_at
(D)
6

Gender Dx

Aging
Clozapine
14

ubiquitin

DE/6

F-PSYCHOSIS

Alcohol

conjugating

86.8%

L: (2/13)

ASD

enzyme E21

0.91/3.78E−02

Hallucinations

F-SZA

Mood State

L: (2/8)

Stress

0.92/4.78E−02

FOXO3
231548_at
(I)
4

Gender Dx

Gender Dx

BP
Clozapine
14

forkhead box

AP/2

F-SZA

M-PSYCHOSIS

Cocaine

O3

38.9%

C:

(5/15)

C:

(5/47)
Longevity

(I)

0.78/4.32E−02

4.14/4.58E−02
PTSD

DE/6

Stress

82.3%

Suicide

THRA

214883_at
(I)
8

Gender Dx

Alcohol
3,5-
14

thyroid

DE/4

F-BP

PTSD
diiodothyropropionic

hormone

61.3%

C: (6/19)

Stress
acid,denosum

receptor,

0.79/2.18E−02

Suicide
ab/levothyrox

alpha

M-BP

SZ
ine,amiodaro

L: (1/27)

ne,levothyrox

1/4.76E−02

ine,dextrothy

roxine,L-

triiodothyronine

ITPKB
1554306_at
(D)
6

Gender

Acute
Omega-3
14

inositol-

AP/4

Female

Stress
fatty acids

trisphosphate

61.1%

L: (5/32)

Aging

3-kinase B

(D)

0.81/1.37E−02

Alcohol

DE/4

Gender Dx

ASD

55.7%

F-BP

BP

C: (6/19)

MDD

0.91/2.50E−03

Neurological

F-BP

Suicide

L: (2/9)

SZ

1/2.02E−02

IGF1

209542_x_at
(I)
8

Gender Dx

Aggression
Lithium
14

insulin-like

DE/4

F-BP

Aging
Clozapine

growth

54.1%

C: (6/19)

Alcoho
Fluoxetine

factor 1

0.79/2.18E−02

Anxiety
(SSRI),

(somatomedin

BP
Venlafaxine

C)

Depression
(SNRI)

Longevity
MEDI-573,

PTSD
BI836845

SZ

NPTX2

213479_at
(I)
8

Gender Dx

Alcohol
Clozapine
14

neuronal

DE/4

F-BP

Brain
Fluoxetine

pentraxin II

52.5%

L: (2/9)

arousal

0.93/3.95E−02

Cocaine

Depression

MDD

MDD, SZ

Mood

Disorders

NOS

Stress

Suicide

GSTM3

235867_at
(D)
8

Gender Dx

BP

14

glutathione

DE/4

F-SZA

MDD

S-

52.1%

C: (5/15)

SZ

transferase

0.78/4.32E−02

mu 3 (brain)

BACE1

222463_s_at
(I)
8

Gender

MDD

14

Beta-

DE/2

Male
Stress

Secretase 1

44.8%

C: (7/91)
Suicide

1.97/3.78E−02

PSEN1

203460_s_at
(D)
9

Aging
Omega-3
13

presenilin 1

DE/4

Alcohol
fatty acids

54.5%

Autism

Depression

Emotional

Stability

Neuroticism

Suicide

SZ

GFAP
203540_at
(I)
9

Gender Dx

Addictions
Omega-3
13

glial

DE/2

F-BP

Alcohol
fatty acids

fibrillary

34.3%

C: (6/19)

BP
Clozapine

acidic protein

0.77/3.28E−02

MDD

Stress

Suicide

SZ

Yohimbine

TREM2

219725_at
(I)
11

BP

13

triggering

DE/2

SZ

receptor

37.6%

expressed on

myeloid cells

2

NOCT
220671_at
(D)
6

Gender Dx

PTSD

12

nocturnin

AP/4

F-PTSD

Post-

69.5%

C:

(3/9)

Deployment

1/1.01E−02

PTSD

CEP350
204373_s_at
(D)
6

Gender Dx

Autism
Antidepressants,
12

centrosomal

DE/4

M-PSYCHOSIS

BP
Fluoxetine

protein

67.1%

L:

(2/22)
Cocaine

350 kDa

54.6/3.77E−02
Depression

PTSD

Stress

Suicide

SZ

PPP2R2B
205643_s_at
(I)
6

Gender Dx

ADHD

12

protein

DE/4

F-BP

Aging

phosphatase

63.5%

L:

(2/9)

Alcohol

2, regulatory

1/2.02E−02

ASD

subunit B,

Circadian

beta

abnormalities

Longevity

PTSD

Suicide

SZ

NRP2
222877_at
(I)
6

Gender Dx

Longevity
Clozapine
12

neuropilin 2

DE/4

M-MDD

MDD

61.3%

L: (3/18)

Phencyclidine

0.98/5.43E−03

Stress

CTSS

232617_at
(D)
8

Aging
Omega-3
12

cathepsin S

DE/4

Alcohol
fatty acids

56.9%

ASD

BP

Brain

arousal

Pain

Suicide

VEGFA
211527_x_at
(I)
8

Gender Dx

Alcohol
Antipsychotics
12

vascular

DE/2

M-MDD

Anxiety
Fluoxetine

endothelial

45.3%

C:

(11/38)

BP
Steroids

growth factor

0.7/2.57E−02

Chronic

A

Stress

Depression

Hallucinations

Intellect

MDD

.

Pain MSK

Stress

Suicide

SZ

MAPT

233117_at
(I)
10

Aging
Lithium
12

microtubule

DE/2

Alcohol
Omega-3

associated

44.2%

Intellect
fatty acids

protein tau

MDD

Methamphetamine

Phencyclidine

Stress

Suicide

SZ

GSK3B

240562_at
(I)
10

Aging
Antipsychotics
12

glycogen

DE/2

Alcohol
Antipsychotics

synthase

39.2%

ASD
Pregnenolone

kinase 3 beta

BP
sulfate

MDD
Fluoxetine

Methamphetamine
(SSRI)

Psychological Stress
Lithium

Stress
mood

Suicide
stabilizing

SZ
drugs

Yohimbine
Valproate

GS1C3B

242336_at
(D)
10

Aging
Astaxanthin-
12

glycogen

AP/2

Alcohol
DHA

synthase

34.1%

ASD
Antipsychotics

kinase 3 beta

BP
Lithium

BP,SZ
Omega-3

MDD
fatty acids

Stress
Ketamine

Suicide
lipoteichoic

SZ
acid

Valproate

enzastaurin,

glycogen

synthase

kinase-3beta

inhibitor

BACE1

224335_s_at
(I)
8

MDD

10

Beta-

DE/2

Stress

Secretase 1

43.1%

Suicide

Bold-top biomarkers after discovery and prioritization (n = 23, CFG ≥ 12)). Underlined-best predictor in a category after testing of the longer list candidate biomarkers after discovery and prioritization (n = 138, CFG ≥ 10), as depicted in Figure 3. We tabulated into a convergent functional evidence (CFE) score all the evidence from discovery (up to 6 points), prioritization (up to 12 points), testing (State Memory Retention State and Trait Future Positive Neuropsychological Testing (up to 6 points each if significantly predicts in all subjects, 4 points if predicts by gender, 2 points if predicts in gender/diagnosis subgroups). The goal is to highlight, based on the totality of our data and of the evidence in the field to date, biomarkers that have all around evidence: track memory, are implicated in AD, and predict memory state and future dementia. Such biomarkers merit priority evaluation in future clinical trials. As depicted in Figure 1B, the top row of values-increased in expression (I) in high memory, bottom row of values-decreased in expression (D) in high memory. DE-differential expression, AP-Absent/Present. “C”-Cross-sectional analyses; “L”-Longitudinal analyses, using levels and slopes from multiple visits. In All, by Gender, and personalized by Gender and Diagnosis (Gender/Dx). “DE”-differential expression, “AP”-Absent/Present. For Step 3 Predictions, C-cross-sectional (using levels from one visit), L-longitudinal. “M”-males, “F”-Females. “MDD”-depression, “BP”-bipolar, “SZ”-schizophrenia, “SZA”-schizoaffective, PSYCHOSIS-schizophrenia and schizoaffective combined, “PTSD”-post-traumatic stress disorder.

TABLE 3

Matching with drugs. Evidence for modulation by drugs in same direction as increased memory retention (see also, FIG. 5).

Step 1

Discovery

in Blood
Step 2

(Direction
External

of Change
CFG

tracking
Evidence

Memory
For

Increase
Involvement

Method/
in AD

Genesymbol/

Score/%
Score

Anti-

Gene name
Probesets
Up to 6 pts
Up to 12 pts
Lithium
Omega-3
depressants
Other drugs

APOE
212884_x_at
(D)
11

(D)

apolipoprotein

AP/2

Lymphocytes

E

34.1%

(males)

Omega-3

fatty acids³¹⁸

GSK3B
242336_at
(D)
10
(D)
(D)

(D)

glycogen
209945_s_at
AP/2

olfactory
PFC

HIP

synthase

34.1%

neurons
(females)

Ketamine³²⁰

kinase

(D)

Lithium²⁹⁸
Omega-3

(D)

3 beta

DE/4

Lithium³¹⁹
fatty acids³¹⁸

HIP

50.3%

(D)

lipoteichoic acid³⁰¹

HIP

(D)

Alzheimer's Disease

Caudate putamen

Astaxanthin-DHA⁴³

Valproate²²²

(D)

Frontal Cortex

Antipsychotics³²¹

Enzastaurin

MAPT
203930_s_at
(I)
10
(I)
(I)

microtubule
233117_at
DE/2

Schneider
HIP

associated
203928_at
33.7%

2 (S2) cells
(males)

protein tau

(I)

Lithium³²²
Omega-3

DE/2

fatty acids³¹⁸

44.2%

(I)

DE/4

57.5%

PTGS2
1554997_a_at
(D)
10
(D)

(D)

prostaglan

DE/4

PBMC

Serum, HIP

dinendoperoxide

76%

Lithium¹⁶⁵

Vorinostat³²³

synthase 2

(D)

(prostaglandin

PBMC

G/H synthase

Antipsychotics¹⁶⁵

and

Acetaminophen

cyclooxygenase)

NSAIds

GFAP
203540_at
(I)
9

(I)

(I)

glial fibrillary

DE/2

Brain

AMY, HIP, PFC

acidic protein

34.3%

Omega-3

Clozapine¹⁷¹

fatty acids³²⁴

PSEN1
203460_s_at
(D)
9

(D)

tarenflurbil

presenilin 1

DE/4

Lymphocytes

54.5%

(females)

Omega-3

fatty acids³¹⁸

TGFB1
203084_at
(D)
9

(D)

dalantercept,

transforming

AP/4

Lymphocytes

fresolimumab,

growth factor

54.5%

(females)

LY3200882,

beta 1

Omega-3

MSB0011359C

fatty acids³¹⁸

BACE1
222463_s_at
(I)
8

Beta-Secretase 1
224335_s_at
DE/6

44.8%

(I)

DE/6

43.1%

CTSS
232617_at
(D)
8

(D)

cathepsin S

DE/4

Lymphocytes

56.9%

(females)

Omega-3

fatty acids³¹⁸

GUSB
202605_at
(D)
8

(D)

glucuronidase,

DE/4

VT

beta

55.7%

Clozapine¹⁷¹

IGF1
209542_x_at
(I)
8
(I)

(I)
(I)

insulin-like

DE/4

lymphoblastoid

HIP
VT

growth factor 1

54.1%

cell lines

Fluoxetine
Clozapine¹⁷¹

(somatomedin C)

Lithium³²⁵

(SSRI),

Venlafaxine

(SNRI)³²⁶

NPTX2
213479_at
(I)
8

(I)
(I)

neuronal

DE/4

HIP
VT

pentraxin II

52.5%

Fluoxetine³²⁷
Clozapine¹⁷¹

THRA
214883_at
(I)
8

thyroxine

thyroid hormone

DE/4

receptor, alpha

61.3%

VEGFA
211527_x_at
(I)
8

(I)
(I)

vascular

DE/2

Cortex
Plasma

endothelial

45.3%

Fluoxetine³²⁸
Antipsychotics²⁰⁴

growth factor A

(I)

Blood Steroid³²⁹

GAP43
204471_at
(I)
7

(I)

growth associated

DE/4

Human

protein 43

50.8%

astrocyte-derived

cells (U-87 MG)

Valproate³³⁰

(I)

HIP

Benzodiazepines³³¹

RAB7A
227602_at
(I)
7

(I)
(I)

RAB7A, member

AP/2

basal forebrain
Caudate putamen

RAS oncogene

43.8%

TCA³³²
Valproate²²²

family

(I)

DE/4

69.6%

KIDINS220
214932_at
(I)
6

(I)

kinase

DE/4

VT

D-interacting

51.9%

Clozapine¹⁷¹

substrate

220 kDa

CD36
242197_x_at
(D)
6

(D)

CD36 molecule

DE/4

Lymphocytes

(thrombospondin

67.1%

Benzodiazepines³³¹

receptor)

CEP350
204373_s_at
(D)
6

(D)

centrosomal

DE/4

AMY

protein

67.1%

Antidepressants,

350 kDa

Fluoxetine²²⁵

ITPKB
1554306_at
(D)
6

(D)

inositol-

AP/4

lymphocytes

triphosphate

61.1%

(males)

3-kinase B

(D)

Omega-3

DE/4

fatty acids³¹⁸

55.7%

NRP2
222877_at
(I)
6

(I)

neuropilin 2

DE/4

CP

61.3%

Clozapine¹⁷¹

PER1
242832_at
(I)
6
(I)

(I)

period circadian

DE/4

Cerebral

VT

clock 1

61.3%

cortex (right)

Clozapine¹⁷¹

Lithium³³³

(I)

(I)

AMY

lymphoblastoid

Quetiapine³³⁵

cell lines (LCLs)

derived

Lithium³³⁴

UBE21
233360_at
(D)
6

(D)

ubequitin

DE/6

VT

conjugating

86.8%

Clozapine¹⁷¹

enzyme E2I

FOXO3
231548_at
(I)
4

(I)

forkhead

AP/2

Lymphocytes,

box O3

38.9%

VT Clozapin¹⁷¹

(I)

DE/6

82.3%

RHEB
243008_at
(D)
4

(D)

Ras homolog

AP/6

NR1³³⁶

enriched in brain

84.4%

(D)

DE/4

64.1%

UBE2L3
200682_s_at
(D)
4

(D)

ubiquitin

DE/6

VT

conjugating

91%

Clozapine¹⁷¹

enzyme E2L 3

Tables 4A & 4B. Methods for Personalized Assessment of Memory State (Table 4A) and Prediction of Future Risk for Alzheimer and Related Disorders (Table 4B). Personalized by Gender and Psychiatric Diagnosis.

M—males; F—females; BP—bipolar; MDD—Major Depressive Disorder; PTSD—Post-Traumatic Stress Disorder; PSYCHOSIS—schizophrenia or schizoaffective disorder; SZ—schizophrenia; SZA—schizoaffective disorder; I—increased; D—decreased.

N—

TABLE 4A

Assessment for Memory State

Direction of

Change in Low

Diagnosis
Best Individual Biomarker
Memory

M-BP
NAV2
D

M-BP
UBE2L3
I

M-MDD
CD40
I

M-MDD
LOC101928123
D

M-PSYCHOSIS
ARSB
D

M-PTSD
TGFB1
I

M-SZ
NKTR
I

M-SZA
ARSB
D

M-SZA
CD36
I

F-BP
CACNA1S
D

F-BP
ITPKB
I

F-PSYCHOSIS
SERTAD3
I

F-PSYCHOSIS
LINC01398
D

F-PTSD
NOCT
I

F-SZA
SERTAD3
I

F-SZA
LINC01398
D

TABLE 4B

Prediction of Future Risk for Alzheimer's and Related

Disorders

Direction of

Change in Low

Diagnosis
Best Individual Biomarker
Memory

M-BP
KIDINS220
D

M-PSYCHOSIS
CEP350
I

M-PSYCHOSIS
CALHM1
D

M-SZ
RHEB
I

M-SZ
MAPT
D

Tables 5A-5C. New Therapeutics. Discovery of new method of use for drugs/repurposing. Table 5A. Connectivity Map (CMAP) analysis. Query for signature is done using exact Affymetrix probe sets and direction of change. Drugs that have same gene expression profile effects to our high memory retention biomarkers signatures. A score of 1 indicates the perfect match, i.e. the best potential therapeutic for increasing memory retention. Table 5B. NIH LINCS analysis using the L1000CDS2 (LINCS L1000 Characteristic Direction Signature Search Engine) tool. Query for signature is done using gene symbols and direction of change. Shown are compounds mimicking direction of change in high memory. A higher score indicates a better match. Table 5C. CRowd Extracted Expression of Differential Signatures (CREEDS) analysis. Query for signature is done using gene symbols and direction of change. Shown are compounds mimicking direction of change in high memory. A higher score indicates a better match.

Table 5A. Drug repurposing using Connectivity Map (CMAP from Broad Institute/MIT)

TABLE 5A1

Drugs Identified Using Gene Expression Panels of Top Biomarkers CFG ≥ 12

(n = 23 probe sets; 7 increased and 6 decreased were present in HG-U133A

array used by CMAP).

Panel of genes increased in expression: MAPT (2 probe sets), TREM2, GFAP,

THRA, IGF1, NPTX2

Panel of genes decreased in

expression: NPC2, GSK3B, GUSB, TGFB1, APOE, PSEN1

rank
CMAP name
score
Description

1
verteporfin
1
A benzoporphyrin derivative, it is a medication used as

a photosensitizer for photodynamic therapy to eliminate

the abnormal blood vessels in the eye associated with

conditions such as the wet form of macular

degeneration.

2
pioglitazone
0.987
A drug of the thiazolidinedione (TZD) class with

hypoglycemic (antihyperglycemic, antidiabetic) action,

used to treat diabetes. PPAR gamma agonist. There is

evidence to suggest piolitazone is associated with a

lower risk of dementia in type 2 diabetics. Phase 3

clinical trials failed to meet endpoints using

pioglitazone as a therapeutic for MCI/AD.

3
salsolidine
0.972
A tetrahydroisoquinoline isolated from plants of the

genus Salsola. Tetrahydroisoquinolines are

steroselective competitive inhibitors of the enzyme

MAO. They are also a competitive inhibitors of

COMT.

4
sulfadimidine
0.97
A sulfonamide antibacterial.

5
SB-203580
0.968
Specific inhibitor of p38MAPK.

6
ronidazole
0.966
An antiprotozoal agent used in veterinary medicine.

7
mesalazine
0.961
Anti-inflammatory salycilate derivative used to treat

ulcerative colitis.

8
dioxybenzone
0.946
An organic compound used in sunscreen to block UVB

and short-wave UVA rays. It is a derivative of

benzophenone.

9
metamizole
0.942
A non-steroidal anti-inflammatory drug.

10
8-azaguanine
0.936
A purine analog with antineoplastic activity.

11
sulfaphenazole
0.935
A long-acting sulfonamide antibiotic used in the

treatment of leprosy.

12
dicoumarol
0.933
A naturally occurring anticoagulant drug that depletes

stores of vitamin K. In general, vitamin K antagonists

may have a negative influence on visual memory,

verbal fluency, and brain volume.

13
tolazamide
0.915
An intermediate-acting, first-generation sulfonylurea

with hypoglycemic activity.

14
pipemidic acid
0.911
A member of the pyridopyrimidine class of

antibacterials.

15
NS-398
0.911
A COX-2 inhibitor. May acutely prevent the

suppression of hippocampal long-term plasticity by

amyloid beta.

16
morantel
0.901
An anthelmintic drug used for the removal of parasitic

worms in livestock. An inhibitor of

acetylcholinesterase.

17
indapamide
0.901
A thiazide-like diuretic drug generally used in the

treatment of hypertension, as well as decompensated

heart failure. Indapamide has been shown to suppress

the production of amyloid beta and improve clearance.

18
promazine
0.893
Blocks postsynaptic dopamine receptors D1 and D2 in

the mesolimbic and medullary chemoreceptor trigger

zone. Has significant interaction with multiple

Alzheimer target proteins.

19
tinidazole
0.893
A nitroimidazole antitrichomonal agent effective

against Trichomonas vaginalis, Entamoeba histolytica,

and Giardia lamblia infections.

20
estradiol
0.892
An estrogen steroid hormone. There is evidence that

suggests lifetime exposure to estrogen seems to lower

risk of AD. Women who began estradiol treatment

within one year of menopause had preserved metabolic

activity in regions in and around the hippocampus. It is

unclear whether above the age of 50 years, if

estrogen/estradiol is protective against AD.

TABLE 5A2

Drugs Identified Using Gene Expression Panels of Top

Biomarkers CFG ≥ 10 (n = 138 probe sets; 45 increased

and 38 decreased were present in HG-U133A array used by

CMAP).

Panel of genes increased in expression: BCAM, HFE, SLC1A7, FTL,

MAPT, GFAP, LDLR, SNCA, THRA, C4A, TREM2, CSF1, SNCA,

VEGFA, IL1A, SNCA, CSF1, NRP2, GAP43, CHAT, KIDINS220,

NPTX2, ANK1, IGF1, IGHG1, MAPT, FXYD1, LMNA, ANK1, IGHG1,

AXL, THRA, PPP2R2B, ANK1, RGS10, FCGR1A, LMNA, ITGB5,

APOA1, ZBTB16, OPHN1, ARG2, TSPAN5, AIMP2, RPL38.

Panel of genes decreased in expression: APOE, VEGFA, HSPA5,

ZFP36L1, TGFB1, NDUFA5, DKK1, NOCT, WDR45, IGF1,

CSF1R, ICAM1, VEGFA, ABCA7, GSK3B, GAPDH (2), SREBF1,

DUSP6, UQCRC1, TPK1, MICA, PSEN1, PSMA4, GUSB, NDUFS3,

BST2, TYROBP, CEP350, FDPS, MTF2, NPC2, SERTAD3, HSBP1,

SEC24A, SNRK, TRIM38, UBE2L3.

rank
CMAP name
score
Description

1
levonorgestrel
1
Progesterone derivative used as contraceptive.

Progesterone and its derivatives have some evidence for

promoting brain cell growth, at least in adult rats, and some

studies have shown that it can improve cognitive

performance in the aging mouse.

2
aminohippuric
0.955
Non-toxic diagnostic tool to measure effective renal plasma

acid

flow.

3
meglumine
0.933
Meglumine, also known as megluminum or

methylglucamine, belongs to the class of organic

compounds known as hexoses. Often used as an excipient

in pharmaceuticals. Methylglucamine orotate is a memory-

improving drug, although the ortoate component was

thought to be the active compound.

4
mesalazine
0.932
Non-steroidal anti-inflammatory drug used to

treat inflammatory bowel diseases.

5
lymecycline
0.92
Tetracycline antibiotic; tetracyclines have been shown to

have beneficial effects in neurodegenerative diseases.

6
torasemide
0.918
Diuretic.

7
dioxybenzone
0.916
Sunscreen compound.

8
ginkgolide A
0.915
A natural compound with neuroprotective and possible AD

preventing effects.

9
rimexolone
0.907
Rimexolone is a derivative of prednisolone, a synthetic

glucocorticoid with anti-inflammatory and

immunosuppressive property.

10
ketanserin
0.905
Ketanserin is a selective serotonin receptor antagonist with

weak adrenergic receptor blocking properties. Effective in

lowering blood pressure in essential hypertension. Also

inhibits platelet aggregation. Well tolerated in older

patients.

11
dicloxacillin
0.903
A Penicillin-class antibacterial.

12
talampicillin
0.898
A beta lactam antibiotic from the penicillin family.

13
sulfadimidine
0.897
A sulfonamide antibacterial.

14
naringin
0.892
Naturally occurring flavinoid in citrus fruits, especially

grapefruit. There is evidence in studies with rats that

narigin acts through inhibition of oxidative cellular stress

which attenuates autophagic stress especially in the

hippocampus. Furthermore, there is evidence that ICV-STZ

rats chronically treated with naringin dose dependently

restored cognitive deficits.

15
naproxen
0.891
Nonsteroidal anti-inflammatory drug. Several large scale

studies have demonstrated that long term treatment with

naproxen confers no protection against cognitive decline.

16
flunixin
0.888
A nonsteroidal anti-inflammatory drug, analgesic, and

antipyretic used in horses, cattle and pigs.

17
tubocurarine
0.887
A neuromuscular blocker and active ingredient in curare;

chloride

plant based alkaloid of Menispermaceae. There is evidence

that anticholinergics in general are associated with future

incidence of dementia.

18
cyanocobalamin
0.885
Vitamin B12. There is evidence that increased plasma

levels of homocysteine (which can be caused by low levels

of vitamin B12) is a strong and independent risk factor for

the development of dementia and AD.

19
dequalinium
0.883
A topical bacteriostat. There is evidence that dequalinium

chloride

induces protofibril formation of alpha-synuclein.

20
meticrane
0.882
A sulphonamide-derivative with thiazide-like diuretic

activity.

TABLE 5A3

Drugs Identified Using Gene Expression Panels of Predictive

Biomarkers in All (n = 16 probe sets/genes; 5 increased and 11

decreased were present in HG-U133A array used by CMAP).

Panel of genes increased in expression: FCGR1A, GAP43, MAPT, HFE, RGS10,

Panel of genes decreased in expression: NDUFA5, SEC24A, PSMA4,

UBE2L3, NPC2, GUSB, TGFB1, TRIM38, CD40, ZNF345, IGF1.

rank
CMAP name
score
Description

1
mesalazine
1
Non-steroidal anti-inflammatory drug used to

treat inflammatory bowel diseases.

2
mepenzolate
0.985
An oral, quaternary anticholinergic gastrointestinal agent

bromide

used for adjunctive treatment of peptic ulcer disease.

3
ozagrel
0.974
Antiplatelet agent working as a thromboxane A2 synthesis

inhibitor. Commonly used in the treatment of stroke.

4
protriptyline
0.954
A tricyclic antidepressant that increases the synaptic

concentration of serotonin and/or norepinephrine. In vitro,

protriptyline has been shown to inhibit

acetylcholinesterase, β-secretase, amyloid β aggregation,

and glycation induced amyloid aggregation-all causal

factors in AD progression (Bansode et al. 2014)

5
guanfacine
0.945
A selective alpha_2A-adrenoreceptor agonist that is used as

an antihypertensive. It also preferentially binds

postsynaptic alpha_2A-adrenoreceptors in the prefrontal

cortex which allows its use in improving symptoms

associated with ADHD. It is not a CNS stimulant.

6
saquinavir
0.94
An anti-retroviral protease inhibitor commonly used in the

treatment of HIV.

7
tomatidine
0.938
A steroidal alkaloid that has been found in the skins and

leaves of tomatoes. It suppresses NF-κB signaling in LPS-

stimulated macrophages, blocking induced expression of

inducible nitric oxide synthase and COX-2.

8
eldeline
0.936

9
zuclopenthixol
0.931
An antipsychotic agent working as an antagonist at D1 and

D2 dopamine receptors.

10
fenoterol
0.929
A synthetic adrenergic β₂-agonist that is used as a

bronchodilator and tocolytic.

11
vincamine
0.929
A monoterpenoid indole alkaloid obtained from the leaves

of Vinca minor with a vasodilatory property.

12
imipenem
0.926
A carbapenem antibacterial.

13
isradipine
0.924
A second generation calcium channel blocker that is used

to treat hypertension.

14
3-hydroxy-DL-
0.919
A metabolite of tryptophan, which filters UV light in the

kynurenine

human lens.

15
amiodarone
0.912
A class III antiarrhythmic agent, amiodarone blocks the

myocardial calcium, potassium and sodium channels in

cardiac tissue, resulting in prolongation of the cardiac

action potential and refractory period. In addition, this

agent inhibits alpha- and beta-adrenergic receptors,

resulting in a reduction in sympathetic stimulation of the

heart, a negative chronotropic effect, and a decrease in

myocardial oxygen demands.

16
lansoprazole
0.911
A proton pump inhibitor (PPI) and a potent inhibitor of

gastric acidity.

17
nialamide
0.911
A non-selective, irreversible monoamine oxidase inhibitor

of the hydrazine class that was used as an antidepressant. It

was withdrawn by Pfizer several decades ago due to the

risk of hepatotoxicity.

18
hydralazine
0.909
An antihypertensive with vasodilatory effects.

19
S-propranolol
0.906
The active enantiomer of propranolol, a β-adrenergic

receptor antagonist.

20
nomifensine
0.906
A norepinephrine-dopamine reuptake inhibitor.

TABLE 5A4

Drugs Identified Using Gene Expression Panels of Predictive

Biomarkers in Males (n = 17 probe sets/genes; 6 increased and 11

decreased were present in HG-U133A array used by CMAP).

Panel of genes increased in expression: FCGR1A, GAP43, MAPT,

KIDINS220, AIMP2, RGS10

Panel of genes decreased in expression: NDUFA5, SEC24A, PSMA4, UBE2L3,

NPC2, BST2, TGFB1, TRIM38, ZNF345, IGF1, VEGFA

rank
CMAP name
score
Description

1
natamycin
1
Ophthalmic antifungal suspension.

2
mepenzolate
0.9
An oral, quaternary anticholinergic gastrointestinal agent

bromide

used for adjunctive treatment of peptic ulcer disease.

3
valinomycin
0.896
A natural antibiotic derived from Streptomyces. It also

binds potassium ions and facilitates their transfer across

lipid bilayers.

4
aminohippuric
0.881
Non-toxic diagnostic tool to measure effective renal

acid

plasma flow.

5
dexpropranolol
0.859
A non-selective β-adrenergic blocker. Studies have shown

propranolol reduces cognitive deficits and amyloid/tau

pathology in AD simulated mice.

6
valproic acid
0.851
A histone deacetylase inhibitor commonly used as an

anticonvulsant and antimanic agent. Studies show valproic

acid enhances memory and cognition in mice models.

7
dicloxacillin
0.85
A penicillin antibiotic.

8
pronetalol
0.837
An early non-selective β-blocker candidate that was not

used clinically as it formed a carcinogenic metabolite in

mice.

9
iobenguane
0.837
A guanidine analog with specific affinity for tissues of the

sympathetic nervous system. The radiolabeled forms are

used as antineoplastic or radioactive imaging agents. May

be useful for diagnosing AD or dementia with Lewey

bodies.

10
todralazine
0.829
An antihypertensive agent with central and peripheral

action. It has some CNS depressant effects as well.

11
torasemide
0.827
An anilinopyridine sulfonylurea belonging to the class of

loop diuretics.

12
gallamine
0.824
A non-depolarising muscle relaxant. It acts by combining

triethiodide

with the cholinergic receptor sites in muscle and

competitively blocking the transmitter action of

acetylcholine.

13
sulconazole
0.822
An antifungal medication of the imidazole class.

14
chlormezanone
0.82
A non-benzodiazepine muscle relaxant. It was

discontinued worldwide in 1996 due to rare but serious

cases of toxic epidermal necrolysis.

15
amantadine
0.818
A primary amine that has both antiviral and dopaminergic

activity and is used in the therapy of influenza A and

management of Parkinson disease.

16
tubocurarine
0.818
A neuromuscular blocker and active ingredient in curare;

chloride

plant based alkaloid of Menispermaceae.

17
protriptyline
0.805
A tricyclic antidepressant.

18
indometacin
0.8
A nonsteroidal anti-inflammatory drug (NSAID).

19
thioguanosine
0.799
A thio analogue of the naturally occurring purine base

guanine used to treat acute myeloid leukemia, acute

lymphocytic leukemia, and chronic myeloid leukemia.

20
adenosine
0.797
A nucleotide that is found in RNA.

phosphate

TABLE 5A5

Drugs Identified Using Gene Expression Panels of Predictive Biomarkers

in Females (n = 13 probe sets/genes; 1 increased and 4 decreased were present

in HG-U133A array used by CMAP).

Panel of genes increased in expression: CHAT

Panel of genes decreased in expression: GUSB, CD40, SERTAD3, TBRG4

rank
CMAP name
score
Description

1
benserazide
1
Peripherally acting aromatic L-amino acid decarboxylase

or DOPA decarboxylase inhibitor, which is unable to

cross the blood-brain barrier. Recent studies by Jonkers

et al. and Shen et al. revealed that benserazide can enter

the brain and affect levodopa metabolism.

2
TTNPB
0.99
Selective and highly potent retinoic acid analog with

affinity for retinoic acid receptors (RAR) α, β, and γ,

which are nuclear transcription factors. Activation of

RAR and RXR is known to impede the pathogenesis of

AD in mice by inhibiting accumulation of amyloids.

3
suxibuzone
0.979
Analgesic used for joint and muscular pain.

4
15-delta
0.962
Prostaglandin J derivative. It has a role as a metabolite,

prostaglandin J2

an electrophilic reagent and an insulin-sensitizing drug.

Koma et al. found 15d-PGJ2-impaired memory retrieval

significantly. Pereira et al. concluded therapeutic

potential of targeting the J2 prostaglandin pathway to

prevent/delay neurodegeneration associated with

neuroinflammation

5
hydroquinine
0.961
Anti-arrhythmia agent and parasympatholytic.

6
rosiglitazone
0.954
An antidiabetic drug in the thiazolidinedione class. It

works as an insulin sensitizer, by binding to the PPAR in

fat cells and making the cells more responsive to insulin.

Rosiglitazone reverses memory decline and hippocampal

glucocorticoid receptor down-regulation in an

Alzheimer's disease mouse model (Escribano 2009). In

Phase 2 clinical trials for determining role in learning and

memory in patients diagnosed with MCI.

7
colchicine
0.942
An anti-inflammatory which acts by inhibition of

microtubule polymerization. Impairs memory function in

a dose-dependent manner and is used as a model to

induce Alzheimer's disease in rats.

8
2,6-
0.942
—

dimethylpiperidine

9
primaquine
0.939
An antimalarial agent that acts by interfering with the

mitochondria of parasites.

10
15-delta
0.931
Prostaglandin J derivative. It has a role as a metabolite,

prostaglandin J2

an electrophilic reagent and an insulin-sensitizing drug.

Koma et al. found 15d-PGJ2-impaired memory retrieval

significantly. Pereira et al. concluded therapeutic

potential of targeting the J2 prostaglandin pathway to

prevent/delay neurodegeneration associated with

neuroinflammation

11
meropenem
0.925
Carbapenem antibiotic.

12
anabasine
0.924
A nicotine analog that is an alkaloid. Has demonstrated

improvement in memory and attention in rats.

13
cyclizine
0.919
A piperazine-derivative antihistamine used as an

antivertigo/antiemetic agent.

14
norcyclobenzaprine
0.919
A metabolite of cyclobenzaprine (a muscle relaxant).

15
naftopidil
0.918
An α1-adrenergic receptor antagonist.

16
BAS-012416453
0.914
—

17
AG-012559
0.912
—

18
terbutaline
0.91
A β2 adrenergic receptor agonist.

19
clomipramine
0.908
A tricyclic antidepressant used in the therapy of

obsessive-compulsive disorder. Associated with

diminished metamemory and impaired priming and

working memory.

20
methyldopa
0.904
An antihypertensive that is a competitive inhibitor of the

enzyme DOPA decarboxylase which converts L-DOPA

into dopamine. Has been associated with verbal memory

impairment.

Table 5B. Drug repurposing using L1000 Characteristic Direction Signature Search Engine.

TABLE 5B1

Drugs Identified Using Gene Expression Panels of Top Biomarkers CFG ≥

12 (n = 18 unique genes; 8 increased and 10 decreased).

Panel of genes increased in expression: MAPT, GFAP, TREM2, ARSB,

IGF1, THRA, NPTX2

BACE1

Panel of genes decreased in expression: GSK3B, NPC2, PTGS2, PSEN1,

CTSS, GSTM3, UBE2I, GUSB, APOE, TGFB1

Rank
Score
Drug
Description

1
0.2778
BRD-K03371390

2
0.2778
NCGC00185923-01

3
0.2222
BENZANTHRONE
Dye that binds to amyloid fibrils.

4
0.2222
SQ 22536
Adenylyl cyclase inhibitor.

5
0.2222
ICARIIN
Prenylated flavanol glycoside from Epimedium

sagittatum. Jin et al. 2014 has found that Icariin

significantly improved learning and memory of

transgenic mice models of AD via stimulation of

the NO/cGMP pathway. Sheng et al. 2017

concluded that Icariin improves synaptic

plasticity, and therefore learning and memory, in

rat models of AD via the BDNF/TrkB/Akt

pathway.

6
0.2222
YM 90709
IL-5 receptor antagonist.

7
0.2222
QUIPAZINE
Binds to serotonin receptors, particularly to

MALEATE
5HT2A and 5HT3.

8
0.2222
Cisapride
Serotonin 5-HT₄receptor agonist. Galeotti et al.

1997 revealed that cisapride prevented

dicylomine-induced amnesia in mice suggesting

it plays an important role in modulation of

memory processes. No further studies have been

published.

9
0.2222
LEUCINE
Enkephalin. Meilandt et al. 2008 found that

ENKEPHALIN
enkephalin elevations may contribute to

cognitive impairments in mice models of AD.

10
0.2222
MLN4924
An ubiquitin-like protein with roles relevant to

cellular processes important for cancer cell

survival.

11
0.2222
2-(trifluoromethyl)-

10H-phenothiazine

12
0.2222
brucine
An alkaloid antagonist at glycine receptors and

paralyzes inhibitory neurons. It is a low potency

M₁positive allosteric modulator.

There is high expression of M₁in areas of the

brain responsible for learning, cognition, and

memory.

13
0.2222
Clodronate
A bisphosphonate that affects calcium

metabolism and inhibits bone resorption. Park

et al. 2017 concluded that in mice studies

clodronate diminishes brain perivascular

macrophages which prohibits amyloid-beta

from damaging brain blood vessels.

However, this effect is limited to a few weeks.

14
0.1667
Vincristine sulfate
An alkaloid that irreversibly binds to

microtubules and spindle proteins. It is an

antineoplastic agent used to treat a variety of

cancers.

15
0.1667
AZ 10417808
A selective caspase-3 inhibitor.

16
0.1667
CCCP
A proton ionophore.

17
0.1667
Flurofamide
A potent inhibitor of bacterial urease.

18
0.1667
Chelidonine (+)
An inhibitor of tubulin polymerization inducing a

G2/M mitotic arrest. Dickey et al. 2006 reported

that chelidonine reduced tau levels in vitro.

19
0.1667

Commonly known as turmeric. It is a scavenger

of oxygen species and inhibits lipid peroxidation

as well as peroxide-induced DNA damage. Small

et al. 2018 found that daily oral curcumin may

lead to improved memory and attention in non-

demented adults. Zhang et al. 2006 concluded

that curcumin may enhance amyloid-beta uptake

by macrophages in AD patients.

Lin et al. 2008 reported that curcumin

significantly blocks the formative effect of iron

on neurofibrillary tangles in vitro.

Several studies have revealed anti-Alzheimer's

effects in mice and rat models (Lim et al. 2001,

Garcia-Alloza et al. 2007, Ahmed et al. 2011).

20
0.1667
rizatriptan
A selective agonist of serotonin type 1B and

1D receptors.

TABLE 5B2

Drugs Identified Using Gene Expression Panels of Top Biomarkers

CFG ≥ 10 (n = 112 unique genes; 53 increased and 59 decreased).

Panel of genes increased in expression: LMNA, FOXO3, CCND2, PMP22, BCAM,

ELOVL6, HFE, NAV2, SLC1A7, FTL, MAPT, GFAP, LDLR, C4A, SNCA, THRA,

TREM2, CSF1, IL1A, NRP2, GAP43, RCOR1, KIDINS220, CHAT,

NPTX2, PON2, ANK1, IGF1, IGHG1, KLF3, FXYD1, COX6A1

AXL, PER1, SH3RF2, PPP2R2B, CLDN10, RGS10, FCGR1A, ITGB5,

APOA1, WASF2, ZBTB16, OPHN1, ARG2, SHC3, TSPAN5, NLGN3,

ARSB, AIMP2, CSNK1A1, RPL38, BACE1

Panel of genes decreased in expression: GSK3B, APOE, HELZ, VEGFA,

HSPA5, ZFP36L1

TGFB1, NDUFA5, ITPKB, DKK1, NOCT, SLC44A1, RHEB, NKTR, PGK1,

SALL3, WDR45, CSF1R

ICAM1, ABCA7, INPP5D, GAPDH, DUSP6, SREBF1, UQCRC1, TPK1,

GSTM3, MICA, DLD, PSMA4

PSEN1, GUSB, BST2, CD36, NDUFS3, CTSS, MPEG1, TYROBP, B2M,

RNASET2, FNBP1, USPL1

CEP350, FDPS, MTF2, RAB7A, PTGS2, NPC2, LYST, SERTAD3, SEC24A,

HSBP1, SNRK, TRIM38

NUP214, UBE2I, ASPHD2, UBE2L3, ZC3HAV1.

Rank
Score
Drug
Description

1
0.1038
Proparacaine hydrochloride
Local anesthetic

2
0.0943
BRD-K00944562

3
0.0943
BRD-A80151636

4
0.0943
BRD-K05361803

5
0.0943
BRD-K82137294

6
0.0943
BRD-K34206396

7
0.0943
Pioglitazone
A drug of the thiazolidinedione

(TZD) class with hypoglycemic

(antihyperglycemic, antidiabetic)

action, used to treat diabetes

8
0.0849
TENOXICAM
NSAID

9
0.0849
AC-1133

10
0.0849
Vincamine
An antihypertensive with

vasodilatory effects.

11
0.0755
5-nonyloxytryptamine
An 5-HT1B selective agonist.

12
0.0755
CINANSERIN
A serotonin antagonist.

13
0.0755
Phenoxazine
A dye which consists of an

oxazine fused to two benzene

rings.

14
0.0755
elesclomol
An inducer of heat shock protein

70 that activates natural killer cell-

mediated tumor killing.

15
0.0755
curcumin
A scavenger of oxygen species

and inhibits lipid peroxidation as

well as peroxide-induced DNA

damage.

16
0.0755
TOLAZAMIDE
A sulfonylurea with hypoglycemic

activity.

17
0.0755
Gly-Gly-delta-N-(phosphonacetyl)-L-

ornithine

18
0.0755
bestatin
A metalloprotease inhibitor

selective for aminopeptidase.

19
0.0755
levofloxacin
A fluoroquinolone antibiotic.

20
0.0755
valaciclovir
A DNA polymerase inhibitor.

TABLE 5B3

Drugs Identified Using Gene Expression Panels of Predictive Biomarkers in

All (n = 31 genes; 14 increased and 17 decreased).

Panel of genes increased in expression: FCGR1A, GAP43, MAPT, HFE, RGS10,

CALHM1 ARSB, LOC101928760, LOC101928123, RAB7A, TYMSOS,

LOC100499194, ITPKB, LOC105371414

Panel of genes decreased in expression: NDUFA5, SEC24A, PSMA4, UBE2L3,

NPC2, GUSB, TGFB1, TRIM38, CD40, ZNF345, IGF1, LOC101927027,

MIS18BP1, RHEB, CARD11, NKTR, MS4A14

Rank
Score
Drug
Description

1
0.1818
CUNEATIN METHYL ETHER

2
0.1818
GR 159897
A potent and selective NK₂

receptor antagonist.

3
0.1818
Compound 58

4
0.1818
ROLIPRAM
A selective phosphodiesterase-4

inhibitor.

5
0.1818
BRD-K01089529

6
0.1818
BRD-K15888437

7
0.1818
BRD-K17025677

8
0.1818
7618107

9
0.1818
BL-074

10
0.1818
BRD-A79981887

11
0.1818
BRD-A32164164

12
0.1818
BRD-K02562327

13
0.1818
BRD-K74767048

14
0.1364
vorinostat
A histone deacetylase inhibitor.

15
0.1364
curcumin
A scavenger of oxygen species and

inhibits lipid peroxidation as well

as peroxide-induced DNA damage.

16
0.1364
trichostatin A
A histone deacetylase inhibitor.

17
0.1364
JW-7-24-1

18
0.1364
geldanamycin
A benzoquinone antineoplastic

antibiotic isolated from the

bacterium Streptomyces

hygroscopicus.

19
0.1364
MAPP, L-erythro

20
0.1364
Piperacetazine
An antipsychotic prodrug.

TABLE 5B4

Drugs Identified Using Gene Expression Panels of Predictive

Biomarkers in Males (n = 34 genes; 15 increased and 19 decreased).

Panel of genes increased in expression: FCGR1A, GAP43, MAPT,

KIDINS220, AIMP2, RGS10, PER1, RAB7A, KLF3, CALHM1, BACE1,

ARSB, LOC101928123, LOC100499194, ITPKB

Panel of genes decreased in expression: NDUFA5, SEC24A, PSMA4,

UBE2L3, NPC2, BST2, TGFB1, TRIM38, ZNF345, IGF1, VEGFA,

LOC101927027, MIS18BP1, RHEB CARD11, NKTR, MS4A14,

B2M, EPB42

Rank
Score
Drug
Description

1
0.1786
Triamcinolone
A synthetic glucocorticorsteroid.

2
0.1786
N20C hydrochloride
Non-competitive NMDA receptor

open-channel blocker.

3
0.1786
manumycin A
An antibiotic that acts as a potent

and selective farnesyltransferase

inhibitor.

4
0.1786
NCGC00183397-01

5
0.1786
BRD-K71917235

6
0.1786
BRD-A32164164

7
0.1429
L-690,330

8
0.1429
PERHEXILINE
A carnitine CPT1 and CPT2

MALEATE
inhibitor.

9
0.1429
Clobetasol propionate
A corticosteroid.

10
0.1429
GR 159897
A NK2 receptor antagonist.

11
0.1429
NOBILETIN
An O-methylated flavone that has

the activity to rescue bulbectomy-

induced memory impairment.

12
0.1429
ENDECAPHYLLIN
A glucose tetra-(3-

X
nitropropanoate) ester.

13
0.1429
Flurandrenolide
A corticosteroid.

14
0.1429
SDZ WAG 994
A potent and selective A1

adenosine receptor agonist.

15
0.1429
Timolol maleate salt
A non-selective beta-adrenergic

antagonist.

16
0.1429
RHAPONTIN
A crystalline glucoside found in

rhubarb.

17
0.1429
16759925

18
0.1429
simvastatin
A HMG-CoA reductase inhibitor.

19
0.1429
2541665-P2

20
0.1429
Compound 58

TABLE 5B5

Drugs Identified Using Gene Expression Panels of Predictive Biomarkers

in Females (n = 12 genes; 6 increased and 6 decreased).

Panel of genes increased in expression: DEFB104B, LINC01398,

CHAT, RTCB, LOC105371414, PER1

Panel of genes decreased in expression: ITPKB, GUSB, CD40,

SERTAD3, TBRG4, MS4A14

Rank
Score
Drug
Description

1
0.2857
Fluticasone propionate
A synthetic trifluorinated

glucocorticoid receptor agonist.

2
0.2857
Anisomycin
An antibiotic isolated from

various Streptomyces species.

3
0.2857
DIGOXIN
A cardiotonic glycoside

obtained mainly from

Digitalis lanata.

4
0.2857
NICARDIPINE
A calcium channel blockader

HYDROCHLORIDE
with vasodilatory properties.

5
0.2857
BRD-K06593056

6
0.2857
Inhibitor BEC
A competitive inhibitor of

hydrochloride
arginases I and II that causes

NO-dependent smooth muscle

relaxation.

7
0.2857
Emetine
A protein synthesis inhibitor

Dihydrochloride
derived from ipecac root.

Hydrate (74)

8
0.2857
Importazole
A nuclear transport receptor

importin-beta inhibitor.

9
0.2857
Salermide
An inhibitor of SIRT1 and

SIRT2 causing tumor-specific

apoptotic cell death.

10
0.2857
BRD-K72264770

11
0.2857
dibenzyline
An alpha-adrenergic antagonist.

12
0.2857
CGP-60474
A cyclin-dependent kinase

inhibitor.

13
0.2857
HG-5-88-01

14
0.2857
Scopolamin-N-oxide
An antagonist of the

hydrobromide
muscarinic acetylcholine

receptor.

15
0.2857
REV-5901
An antagonist of cysteinyl-

leukotriene receptors.

16
0.2857
TRANS-7-HYDROXY-
A dopamine D3 receptor

PIPAT
ligand.

17
0.2857
Biotin
Vitamin B7.

18
0.2857
NNC 711
An anticonvulsant that works

as a selective inhibitor of

GABA uptake by GAT-1.

19
0.2857
L-693,403 maleate
σ ligand selectivity over the

dopamine D2 receptor.

20
0.2857
W-7 hydrochloride
Calmodulin antagonist.

Table 5C. Drug Repurposing using Crowd Extracted Expression of Differential Signatures (CREED)

TABLE 5C1

Drugs Identified Using Gene Expression Signature of Top Biomarkers

CFG ≥ 12 (n = 18 unique genes; 8 increased and 10 decreased).

Signed

Rank
Name
Jaccard Index
Description

1
Lorazepam
0.00727
A benzodiazepine.

2
Finasteride
0.00656
A 5-alpha reductase inhibitor.

3
Bromhexine
0.00649
An expectorant/mucolytic

agent.

4
Ethinylestradiol
0.00641
A semisynthetic estrogen.

5
Dicumarol
0.00639
Isolated from molding sweet-

clover hay, with anticoagulant

and vitamin K depletion

activities.

6
Letrozole
0.00613
A nonsteroidal inhibitor of

aromatase.

7
Promazine
0.0061
A phenothiazine derivative with

antipsychotic and antiemetic

properties.

8
Diisopropyl
0.00598
An irreversible cholinesterase

Fluorophosphate

inhibitor.

9
Rapamycin
0.00568
A mTOR Inhibitor.

10
Doxorubicin
0.00549
A topoisomerase inhibitor.

11
Artemisinin
0.00542
A sesquiterpene lactone

obtained from Artemisia annua,

which has been recently found

to have potent activity against

many forms of malarial

organisms.

12
Colchicine
0.0054
Microtubule inhibitor.

13
Mifepristone
0.00526
Progestin antagonist.

14
Zopiclone
0.00526
A central nervous system

depressant and a sedative.

15
Amlodipine
0.00526
Calcium channel blocker.

16
Busulfan
0.00524
An alkylating agent used in the

treatment of CML.

17
Rosiglitazone
0.00524
A selective agonist for PPAR

GAMMA.

18
Norethindrone
0.00523
A synthetic progestin.

19
Letrozole
0.00521
A nonsteroidal inhibitor of

aromatase.

20
Omeprazole
0.00517
Proton pump inhibitor.

TABLE 5C2

Drugs Identified Using Gene Expression Signature of Top

Biomarkers CFG ≥ 10 (n = 112 unique genes; 68 increased and 64 decreased).

Signed

Jaccard

Rank
Drug
Index
Description

1
Hydralazine
0.01735
An antihypertensive.

2
Rofecoxib
0.0135
NSAID.

3
Ethylene Glycol
0.0134
Dihydroxy alcohol.

4
Doxycycline
0.01339
A tetracycline antibiotic.

5
Levamisole
0.0131
An anthelmintic drug that has been tried

as an adjuvant to chemotherapy.

6
Suxamethonium Chloride
0.01301
A depolarizing skeletal muscle relaxant.

7
Tiapride
0.013
A D2 and D3 dopamine receptor

antagonist.

8
Bupropion
0.01295
An antidepressant of the aminoketone

class and a non-nicotine aid to smoking

cessation.

9
Promethazine
0.01295
A first generation antihistamine that is

used an antiemetic.

10
Pyrazinamide
0.01278
A synthetic pyrazinoic acid amide

derivative with bactericidal properties

against Mycobacterium tuberculosis.

11
Antimycin A
0.01277
An antibacterial that blocks electron

transport between coenzyme Q and

cytochrome c.

12
Metoprolol
0.01273
Competitive beta-1 adrenergic receptor

antagonist.

13
Catechol
0.01271
It has a role as a genotoxin, an

allelochemical and a plant metabolite.

14
Azathioprine
0.01264
A purine analogue that is used as an

immunosuppressive agent.

15
Gadopentetate
0.01262
A gadolinium-based paramagnetic

Dimeglumine

contrast agent.

16
Epirubicin
0.01247
An anthracycline topoisomerase

inhibitor.

17
Propylene Glycol
0.01246
Used as an organic solvent.

18
Thiabendazole
0.01239
A broad spectrum antihelmintic agent.

19
Leflunomide
0.01231
An immunomodulatory agent.

20
Imatinib
0.01231
Tyrosine kinase receptor inhibitor.

For the top biomarkers (see, Table 5), all the evidence from discovery (up to 6 points), prioritization (up to 12 points), testing (state, trait—up to 6 points each if significantly predicts in all subjects, 4 points if predicts by gender, 2 points if predicts in gender/diagnosis) were tabulated into a convergent functional evidence (CFE) score. The total score could be up to 30 points: 18 from the experimental data and 12 from literature data. The experimental data was weighed more than the literature data.

Example 1

In this example, biomarkers for short-term memory were determined.

Longitudinal studies were conducted in psychiatric disorder subjects, a population enriched in memory retention abnormalities. The subjects had blood gene expression data at multiple testing visits, and were phenotyped at each visit, including with Hopkins Verbal Learning Test (HVLT). Subject's electronic medical records were also available for long term follow-up of outcomes.

In Step 1 Discovery, blood gene expression biomarkers were identified that track memory using a powerful within-subject design in a cohort of subjects who displayed at least a 20% change in the retention measure between different visits (n=159 subjects, with 496 visits), normalized (Z-scored) across genders and various psychiatric diagnoses. In Step 2 Prioritization, a Convergent Functional Genomics approach was used to prioritize the candidate biomarkers in Step 1, using published literature evidence (genetic, gene expression and proteomic), from human and animal model studies, for involvement in AD. In Step 3 Testing, an independent cohort (n=127) from the one used for discovery was examined for whether the top biomarkers prioritized in Step 2 were predictive of memory retention measure (state), and of future positive neuropsychological testing for MCI, AD or other dementia (trait), using electronic medical records follow-up data of the study subjects (up to 12.81 years from initial visit).

The top biological pathways where the candidate biomarkers map were related to LXR/RXR activation, neuroinflammation signaling atherosclerosis signaling, and amyloid processing (Table 2). Co-directionality of expression data provide new mechanistic insights that are consistent with a compensatory/scarring scenario for observed brain pathological changes. The STRING gene interaction analysis (FIG. 2) revealed at least 3 networks. Network 1 (red) includes TREM2, along with GUSB and RHEB; it may be involved in reactivity and inflammatory responses. Network 2 (green) includes MAPT (tau), along with PSEN1 and SNCA; it may be involved in activity and cellular trophicity. Network 3 (blue) includes APOE, along with TGFB1 and FOXO3; it may be involved in connectivity and synaptic integrity. GSK3B is at the overlap of Networks 2 and 3.

The top candidate biomarkers were prioritized for convergent evidence for involvement in AD (Table 5). They also had prior evidence of involvement in other psychiatric and related disorders, providing a molecular underpinning for the possible precursor effects of these disorders in AD.

Gene expression biomarkers that were predictive in independent cohorts of memory state and of future neuropsychological testing positive for cognitive decline were successfully identified. Top predictive biomarkers for state were NKTR, ITPK, RGS10, PERI, and ARSB (FIG. 3A). The AUC ROCs ranged from over 0.7 for all subjects tested to over 0.8 personalized by gender, and over 0.9 personalized by gender and diagnosis. Top predictive biomarkers for trait were KLF3, CEP350, FOXO3, MAPT, and RHEB (FIG. 3B). The Cox Regression Odds Ratios ranged from over 2-fold for all subjects tested to over 4-fold personalized by gender and diagnosis.

RHEB, which represents the best biomarker for male schizophrenia, was identified as a future Alzheimer Disorder Related Dementia predictor in males with schizophrenia (FIG. 4). Subject Phchp098 was a male with schizophrenia (SZ) initially tested in 2009. The subject was first diagnosed with paranoid schizophrenia in 1977. In 2016, he was also diagnosed by neuropsychological testing with ADRD and impaired decision-making capacity. At that time, he was 66 years old. Subject was the only subject so far withan ADRD diagnosis in the independent replication follow-up cohort. We tested RHEB, the best predictive biomarker for males with SZ (FIG. 2B). RHEB levels were Z-scored by gender and diagnosis. Subject Phchp098 had the highest levels of RHEB in the lab testing visit compared to all the subjects with future neuropsychological testing (FIG. 4A) and the highest level of RHEB from all the 111 subjects in that cohort (FIG. 4B).

Based on the studies and analyses, the biomarkers with the top overall convergent functional evidence (CFE) for relevance to memory and AD were NPC2, TGFB1, ARSB, GUSB, and KLF3, and then GSK3B, MAPT (tau), APOE, PSEN1, and TREM2. The fact that key genes for AD brain pathology came out of the unbiased whole-genome discovery was reassuring and served as de facto positive controls for the approach.

Some of the biomarkers are targets of existing drugs, such as lithium, antidepressants, and omega-3 fatty acids (FIG. 5; Table 3), of potential utility in patient stratification and pharmacogenomics approaches. Moreover, the top biomarkers gene expression signature, upon bioinformatics drug repurposing analyses, yielded new drug candidates (such as pioglitazone and levonorgestrel), and natural compounds (such as salsolidine, ginkgolide A and icariin). Thus, the signature can be used for targeted enrollment of patients in clinical trials for these compounds, which would increase the odds of success, and for objectively measuring response to treatment.

The methods described herein provide a novel approach for discovering biomarkers of relevance to Alzheimer's disease, as well as testing the biomarkers in independent cohorts. The results provide evidence for precision medicine, diagnostics and therapeutics. The methods can provide improved early diagnosis of risk and preventive treatment for memory disorders in general, and Alzheimer's disease in particular, that result in decreased quality and quantity of life, at a massive cost to individuals, families and society.

In view of the above, it will be seen that the several advantages of the disclosure are achieved and other advantageous results attained. As various changes could be made in the above methods without departing from the scope of the disclosure, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

When introducing elements of the present disclosure or the various versions, embodiment(s) or aspects thereof, the articles “a”, “an”, “the” and “said” are intended to mean that there are one or more of the elements. The terms “comprising”, “including” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements.

Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATION

STATEMENT OF GOVERNMENT SUPPORT

PCT Information

Provisional Applications (1)